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Abstract
Adult  neurogenesis plays a role in many physiological (memory formation) and 
pathological (stroke, depression) processes. Increased neurogenesis in response to brain injury 
was recently reported and is considered a mechanism of regeneration after neuronal loss. There 
are  evidences  that  numerous  factors  like  glutamate,  inflammation,  and  growth  factors  are 
involved in the post-insult increase of precursors proliferation and differentiation. However the 
mechanism of injury-induced neurogenesis is still poorly understood.
In the present study early neurogenesis in vitro in rat organotypic hippocampal slice 
cultures  (OHC)  was  characterized  and  the  complex  interplay  between  neuronal  damage, 
microglia  activation,  cell  proliferation,  neurogenesis  and  the  role  of  inflammation  after 
oxygen-glucose  deprivation  (OGD) was  investigated.  In  addition  the  effect  of  exogenous 
growth factors, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), brain-
derived neurotrophic  factor  (BDNF)  and nerve growth  factor  (NGF)  on proliferation  and 
neurogenesis in OHC in the absence and presence of injury was studied.
Proliferation was assessed by bromodeoxyuridine (BrdU) incorporation, neurogenesis by 
BrdU-double  labeling  with  doublecortin  (DCX)  or  ß-III  Tubulin,  neuronal  damage  by 
propidium iodide uptake, microglia by OX-42 staining, pro-inflammatory cytokines by real-
time RT-PCR. 
Massive cell proliferation was observed in the glial envelope covering the slice. Glial 
envelope was formed by GFAP or GFAP/Nestin positive astrocytes and activated microglia 
during slice cultivation. The proliferation was lower inside of the slice culture. bFGF and EGF 
showed mitogenic properties in our system by increasing the number of BrdU+ cells.
In addition to the dentate gyrus (DG) OHC included a second neurogenic zone: the 
posterior periventricle (pPV), which is a part of the lateral ventricle wall. This structure lining 
the stratum oriens contained Nestin+ precursors. Morphological and functional differences 
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could be identified between DG and pPV precursor populations. Nestin+ cells with stellar 
morphology were found in the DG, while elongated Nestin+ cells were present in the pPV. 
bFGF treatment induced a fast but short-lasting neurogenic response in the DG while the pPV 
showed a more pronounced and long lasting neurogenic effect of bFGF. 
After exposure of OHC to 40 min OGD microglia activation and upregulation of IL-1ß, 
TNF-α and IL-6 mRNA (2h after OGD) preceded the development of neuronal damage (6h 
after OGD) that was followed by an increase in cell proliferation (16h after OGD). BDNF, 
EGF or NGF treatment attenuated OGD-induced proliferation. Neurogenesis was inhibited 
at 3d after OGD in both neurogenic zones, however the restoration of neurogenesis was 
already observed at 6d. At this time point a significant increase of newly generated neurons 
was found in the pPV compared to control. Number of BrdU/ß-III Tubulin+ neurons was 
significantly increased in the pPV of OGD-exposed OHC by bFGF application.
MK-801, indomethacin or minocycline prevented the OGD-induced neuronal damage, cell 
proliferation  and caused  a  decrease  of  OX-42+ microglia  in  the  damaged  area.  Under 
control conditions MK-801, indomethacin or minocycline induced neurogenesis in the pPV. 
After OGD number of BrdU/DCX+ cells was decreased in the pPV by MK-801 treatment. 
However indomethacin or minocycline did not affect  OGD-induced neurogenesis in the 
pPV. 
In conclusion, this study is the first to show that i) two neurogenic zones, the DG and the 
pPV, are present in interface OHC; ii) the DG and pPV contain neural precursors with 
different  neurogenic  properties.  High  neurogenesis  occur  in  the  pPV  while  low 
neurogenesis is present in the DG of OHC; iii) inflammation is mounted in OHC at early 
time  point  after  OGD.  It  is  associated  with  activation,  migration  and  proliferation  of 
microglia; iv) due to microenvironmental changes neurogenesis in both neurogenic zones is 
inhibited early after OGD (3d) and restored later on (6d). OGD stimulates neurogenesis in 
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the pPV; v) neuroprotection against OGD-induced damage in OHC by anti-inflammatory 
treatment  is  associated  with  intact  neurogenesis.  Taking  together,  these  in  vitro data 
represent the evidences of injury-regulated neurogenesis in relation with inflammation in 
OHC that could be useful for further understanding of mechanisms of neurogenesis and 
anti-inflammatory treatment strategies after cerebral ischemia. 
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1. Introduction
Neuronal loss occurs after different acute (stroke, trauma) or chronic (Parkinson disease, 
Alzheimer disease)  neurodegenerative diseases.  The recent  discovery of  adult  neurogenesis 
opens  the  fascinating  possibility  to  consider  endogenous  stem  cells  proliferation  and 
neurogenesis as a potential mechanism of neuronal repair. 
The presence of a large number of dividing cells in the central nervous system (CNS) has 
been known for almost a century (Allen, 1912) and considered as process of cell renewal. While 
glial  cells  can be reproduced by simple cell  division,  stem cells  proliferation and neuronal 
differentiation of progenitor cells are required for neuron generation.
1.1. Neurogenesis in the CNS
Several neurogenic zones have been reported to retain an ability to generate neurons early 
after  birth,  however  neurogenesis  in  these  regions  is  diminished  following  postnatal 
development . 
Fig. 1.1. Neurogenesis in the adult mammalian brain. Schematic sagittal section through the adult mouse brain. 
DG, dentate gyrus; LV, lateral ventricle; OB, olfactory bulb; RMS, rostral migratory stream; SGZ, subgranular 
zone; SVZ, subventricular zone. This figure was adapted from Doetsch and Scharff, 2001.
There are regions in the adult rodent brain (germinal layers) where neurogenesis has been 
observed to occur throughout life (Fig. 1.1) the subventricular zone (SVZ)  lining the lateral 
ventricle (LV) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG)  with 
additional reports of neurogenesis in the Ammon´s horn  and substantia nigra .
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1.1.1. Neurogenesis in the subventricular zone
In the SVZ, cells are born over a large area adjacent to the LV. From their site of birth, 
chains of young neurons migrate along a complex network of tangential pathways and join the 
rostral migratory stream (RMS), which leads to the olfactory bulb, where new cells differentiate 
into two types of local interneurons, granule and periglomerular neurons . 
1.1.2. Neurogenesis in the hippocampus
Cells born in the SGZ migrate a short distance and differentiate into new granule neurons 
within the DG .  The newborn neurons in the SGZ are long-lived and generate appropriate 
projections  within the existing hippocampal  architecture  .  Since the hippocampus plays an 
important role in learning and memory and exhibits a high degree of structural  plasticity , 
neurogenesis  in  the  adult  hippocampus  may  be  important  for  learning  and  memory  in 
mammalians.
1.1.3. Stem cells and their origin
Stem cells have been characterized as cells  with long-term self-renewal (self-renewal 
throughout the lifetime of the animal) and multipotentiality. Being proliferating, stem cells give 
rise  to  progenitor  cells,  which  exhibit  less  self-renewal  ability  and  unipotentiality  or 
multipotentiality.  The  general  term  to  refer  to  either  a  mixed  or  unknown  proliferating 
population is precursors . Progenitor cells then differentiate into neuronal or glial lineage, giving 
rise to neurons or astrocytes and oligodendrocytes, respectively .
The identity  of  stem cells  is  still  under  discussion.  One of the hypothesis  confirmed 
astrocyte  origin  of  stem cells  has  been  proposed  by  Alvarez-Buylla  with  colleges  .  They 
described the structure of germinal zones and characterized stem cells as glial fibrillary acidic 
protein (GFAP)+ B-type cells with astrocyte morphology. Alvarez-Buylla et al. also reported 
the presence of neuroblasts (A-type), rapidly dividing transiently-amplifying cells (C-type) and 
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ependymal cells (E-type) in the SVZ. An intermediate precursors (D-type), which generate new 
granule neurons (G-type) were identified in the SGZ of the DG . Other hypothesis suggested 
that new neuron could derive from radial glia  or subependymal cells of LV wall (LVw) . 
Neural  precursor  cells  situate  in  a  permissive  microenvironment  (niche)  in  the  neurogenic 
regions. The phenotype that is adopted by neural precursors depends on the location of the stem 
cells in the brain and on the type of cells that are needed in that area .
1.1.4. Experimental detection of cell phenotype
Immunohistochemistry is mainly used to define the cell phenotype. Labeling of specific 
cell structures (receptors, filaments) and metabolites (nuclear, cytoplasmic or synaptic proteins) 
could define not only cell phenotype but also e.g. cell maturation stage, physiological functions 
etc. The characteristics of several cell markers are shown in Table 1.
Table. 1. Cell markers used for immunohistochemical cell characterization
Cell marker Cell type Characteristic References
Stem and progenitor cells
Nestin Neural stem cells
Astrocytes
Undifferentiated 
neuroepithelial cells
Intermediate filament 
protein
Cell marker Cell type Characteristic References
Mash-1 Neuronal Progenitors Transcription factor
Prox-1 Neuronal Progenitors Transcription factor
Proliferating cells
Bromodeoxyuridine 
(BrdU)
Mitotic cells in S-phase
Cells  undergoing  to  DNA 
repair
Apoptotic cells reentering 
the cell cycle
Tymidine analog which 
incorporates into the DNA 
of cells during S-phase of 
cell cycle
Proliferating  cell  nuclear 
antigen (PCNA)
Mitotic cells in G1, S and 
partially G2/M phase
Cells  undergoing  DNA 
repair
Co-factor for DNA 
polymerase delta in S-
phase as well as during 
DNA synthesis associated 
with mechanisms involved 
in DNA damage repair
 
Neuronal cells
Doublecortin (DCX)* Proliferating progenitors 
Neuroblasts 
Microtubule-associated 
protein expressed 
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Migrating neurons 
Differentiating neurons
transiently early after 
division
ß-III Tubulin Young immature neurons
Mature neurons
Neuron-specific marker. 
Starts to be expressed after 
birht and continues 
throughout the neuronal 
life
Neuronal nuclei (NeuN) Mature neurons Neuron-specific  nuclear 
protein expressed on post-
mitotic neurons
Microtubule  associated 
protein-2 (MAP-2)
Mature neurons Cytoskeletal  protein, 
regulats  the  assembly  and 
stability  of  neuronal 
microtubules
Glial cells
Glial  fibrillary  acidic 
protein (GFAP) 
Mature astrocytes
Progenitor cells
Intermediate  filament 
composed in  large part  of 
glial  fibrillary  acidic 
protein
S-100ß Immature  and  mature 
astrocytes
Cytosolic Ca2+-binding 
protein, not “glia specific” 
marker 
Griffonia simplicifolia 
Isolectin B4 (IB4)
Ramified  and  amoeboid 
microglia
Isolectin binds with 
galactose containing 
glycoconjugates (lectin 
receptors)
CD11b/c (OX-42) Microglia
Macrophages
Surface complement 
receptors type 3
*Hippocampal granule neurons still express DCX in mature stage, for 2-4 weeks after birth.
To find out the phenotype of a newly generated cell, proliferating cells are labeled with 
DNA replication marker bromodeoxyuridine (BrdU), a thymidine analog, which incorporates 
into the DNA of all cells during the S-phase of cell cycle . Further cell fate can be investigated 
by double labeling of BrdU with a specific cell marker. 
1.1.5. Factors regulating neurogenesis
Neurogenesis is a complex phenomenon and is affected by many factors (see Table 2). 
Neurogenesis  in  mammals  can  be  upregulated/induced  by  injuries  ,  growth  factors  (GFs), 
neurotransmitters   and  physical  exercise   while  neurogenesis  can  be  downregulated  by 
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depression, stress and age  .  Much research effort  has been invested into understanding the 
mechanism and regulation of adult neurogenesis, and considerable progress has been made over 
the  past  10 years  .  GFs have  been  shown to  play  a  significant  role  in  the mechanism of 
neurogenesis .
1.1.6. Growth factors
Numerous GFs are involved in the regulation of cell proliferation, neurogenesis and cell 
survival in the postnatal and adult brain . The GFs can be classified in 1) GFs families e.g. 
fibroblast growth factor (FGF) family, transforming growth factor family etc.; 2) neurotrophins 
e.g bran-derived neurotrophic factor (BDNF),  nerve growth factor (NGF) etc.;  3)  GFs like 
epidermal growth factor (EGF), stem cells factor (SCF) etc.
Glial cells as supportive cells in the nervous system and endothelial cells are the main 
source of  GFs in  the brain parenchyma.  The biological  functions  of  GFs are  mediated by 
binding of these secreted proteins to their transmembrane tyrosine kinase receptors that causes 
the formation of tyrosine kinase dimers .
Table 2. Factors affecting neurogenesis in the hippocampus and SVZ
Factor
Neurogenesis
DG SVZ References
bFGF Increase increase
BDNF increase increase
EGF decrease decrease
Glutamate decrease n.d.
MK-801 increase increase
Glucocorticoids decrease n.d
Age decrease decrease
Depression decrease n.d.
Enriched environment increase increase
Wheel running increase increase
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Nitric oxide donor increase increase
Global ischemia increase n.d.
Focal ischemia increase increase
n.d.,  not  determined;  bFGF,  basic  fibroblast  growth  factor;  BDNF,  brain-derived  neurotrophic  factor;  EGF, 
epidermal growth factor.
The  ligand-mediated  aggregation  of  the  receptors  allows  them to  phosphorylate  one 
another on intracellular domains and then catalyzes the formation of large signaling complexes 
through the recruitment  of cytosolic and membrane associated proteins.  The newly formed 
complex  of  proteins  activates  several  kinase  pathways:  phosphatidylinositol-3-kinase; 
phospholipase  C-γ and  protein  kinase  C  (PKC),  which  control  cell  proliferation  and 
differentiation, cell growth, synaptogenesis, activity dependent plasticity and cell survival . All 
neurotrophins  bind  with  low  affinity  p75NTR receptors  that  regulate  nuclear  factor-κB 
downstream pathway and control cell division and apoptosis .  Some characteristics of GFs, 
whose mitogenic and neurogenic effects were examined in this work, are present in the Table 3.
Table 3.Characteristics of bFGF, EGF, BDNF and NGF
Growth 
factor Type of receptors Characteristic References
bFGF Family  of  four 
receptors  tyrosine 
kinases: FGFR1-4 
1.  mRNA-encoding  bFGF  is  detected  at  early 
stages of rodent CNS development;
2.  bFGF and it’s  family of  receptors  is  widely 
distributed  in  the  adult  CNS,  especially  in  the 
hippocampus and SVZ;
3. Stimulate proliferation of neural precursors and 
neuronal differentiation;
4. Mitogen for precursor cells isolated from brain 
parenchyma.
EGF Tyrosine  kinase 
EGFR
1. EGF and EGFR not so widely expressed as 
FGF family;
2. EGF receptors are expressed in the germinal 
zones by E15, postnataly in the SVZ and SGZ;
3.  Stimulate  proliferation  of  precursors  in  the 
developing and adult brain;
4.  Stimulate  glial  rather  than  neuronal 
differentiation.
 
BDNF High affinity 
tyrosine kinase 
receptors,TrKB, 
and low affinity 
p75 receptors
1.  High  TrkB  expression  in  the  subependimal 
layer of the LV;
2.  Regulate  development  of  large  amount  of 
neuronal cell types;
3. Stimulate neurogenesis in the SVZ;
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4. Promote the survival of newly generated and 
post-mitotic neurons.
NGF High affinity 
tyrosine kinase 
receptors,TrKA, 
and low affinity 
p75 receptors
1.  Stimulate  neuronal  differentiation  of  neural 
precursors;
2. Stimulate neurite outgrowth; 
3. Regulate neuroprotection and sell survival;
4. Trophic function.
bFGF, basic fibroblast growth factor; BDNF, brain-derived neurotrophic factor; EGF, epidermal growth factor; 
NGF, nerve growth factor.
Since GFs possess a neurogenic effect and can sustain neuronal survival,  GF therapy 
might provide an opportunity for pharmacological manipulations of endogenous neurogenesis 
and treatment of diseases associated with neuronal loss such as cerebral ischemia. 
1.2. Cerebral ischemia
1.2.1. Pathophysiology of ischemic cell death
With an incidence of approximately 250-400 cases in 100 000 and a mortality rate of 
around  30%,  cerebral  ischemia  remains  the  third  leading  cause  of  death  in  industrialized 
countries . Clinically, two major forms of ischemic damage can be distinguished: stroke and 
hemorrhage.  Stroke,  is  the complete  or  partial  interruption of cerebral  blood flow whereas 
hemorrhage  results  from bleeding  into  the  parenchyma,  e.g.  from a  ruptured  aneurysm or 
subarachnoidal artery. 
The experimental ischemia models can be divided into two: global and focal ischemia. 
Global ischemia results from entire carotid artery occlusion or abruptly stopped blood flow after 
cardiac arrest that induces delayed neuronal death of selectively vulnerable CA1 neurons of the 
hippocampus  .  In  contrast,  occlusion  of  a  single  middle  cerebral  artery  (MCAO;  e.g.  by 
thrombus) is an example of focal cerebral ischemia. Focal ischemia gives rise to irreversible 
damage in the core region and a partially reversible injury in the surrounding penumbral zone . 
Different forms of ischemic insult are dependent on the amount and distribution of spared tissue 
as well as the type and severity of cell damage occurrence.
Ischemic injury causes severe neurodegeneration and consequently a loss of normal brain 
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functions   resulting  from  a  complex  sequence  of  pathophysiological  events  including 
excitotoxicity, inflammation and programmed cell death (Fig. 1.2). 
Oxidative phosphorylation is the main mechanism of energy production in the brain 
tissue. Energy is required for cell metabolism and maintenance of the ion gradient. Depletion of 
energy due to restriction of glucose and oxygen delivery leads to the loss of membrane potential 
and depolarization of neurons and glia ,  activation of voltage-dependent Ca2+ channels and 
release of excitatory amino acids (glutamate) into the extracellular space.
Fig. 1.2. Simplified overview of pathophysiological mechanism in ischemic cell death. Deprivation of glucose and 
oxygen leads to energy failure and depolarization of the cell membrane. Activation of glutamate receptors results in 
ATP-depletion  and  significantly  increases  intracellular  Na+  and  Ca2+ levels.  Intracellular  Ca2+  overactivates 
numerous enzyme systems (proteases, lipases, endonucleases, etc.). Free radicals are generated, which damage 
membranes (lipolysis), mitochondria and DNA, triggering programming cells death (apoptosis) and formation of 
cell debris. Free radicals induce the release of pro-inflammatory mediators that leads to microglia activation and 
inflammatory reaction. Complex sequences result in irreversible cell damage and cell death. Diffusion of glutamate 
into the extracellular space can propagate a series of waves of depolarization and spread of damage. IL, interleukin; 
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NO, nitric oxide; COX, cyclooxygenase; TNF, tumor necrosis factor. Adapted from K. Dinkel and modified.
As a result of glutamate-mediated overactivation, Na+ and Cl- influx into the cell that is 
followed  by  passive  transport  of  water  and  cell  swelling.  Release  of  pro-inflammatory 
mediators interleukin (IL)-1ß and tumor necrosis factor (TNF)-α from activated glia as well as 
damaged neurons stimulate  the inflammatory reaction in  the ischemic tissue.  Activation of 
NMDA and AMPA/kainite receptors contribute to Ca2+ overload and activation of photolytic 
enzymes that degrade cytoskeletal proteins. Phospholipase A2 and cyclooxygenase (COX)-2 
generate  free-radical  species,  which  induce  lipid  peroxidation  and  membrane  damage  . 
Activation of neuronal nitric oxide synthase (NOS) produces nitric oxide (NO), which reacts 
with a super-oxide anion to form the highly reactive peroxynitrite, that promotes tissue damage 
. It was demonstrated that application of NMDA receptor antagonists, Ca2+ or Na+ blockers as 
well as free radical scavengers provide protection to neurons against ischemia-induced neuronal 
death . Once neuronal damage has developed, an increase in cell proliferation and neurogenesis 
occurs.
1.2.2. Neurogenesis after cerebral ischemia
Increased  cell  proliferation  and  neurogenesis  in  response  to  cerebral  ischemia  was 
reported and considered as a compensatory mechanism of neuronal loss . Global ischemia gives 
rise  to  enhanced  cell  proliferation  in  the  rodent  SGZ  .  Focal  ischemia  (MCAO)  induces 
neurogenesis in the SGZ  and the SVZ where from cells migrate to the damaged striatum . By 
focal  cortical  injury neurogenesis  can be stimulated in  the cerebral  cortex  with additional 
increase of neurogenesis in the DG . 
The mechanisms regulating ischemia-induced neurogenesis are only partly understood. 
Expression  of  developmental  transcription  factors  by  precursors  proliferating  following 
ischemic insult provides evidence that neurogenesis could proceed as it does during embryonic 
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development  .  Ischemia  induces  a  number  of  factors  that  might  underlie  the  neurogenic 
response to insult, including erythropoetin , vascular endothelial growth factor , SCF, heparin-
binding EGF and basic FGF (bFGF) . bFGF and SCF receptors are induced in the SVZ and 
SGZ after focal ischemia . In addition to neurogenic effect, GFs can sustain the survival of 
damaged neurons. It was shown that preconditioning is a phenomenon in which a brief ischemic 
insult induces tolerance against a subsequent severe ischemic insult stimulates GFs expression 
and neurogenesis in adult rat hippocampus . 
Glutamate receptor activation seems to play a prominent role in mediating the neurogenic 
response to ischemia . Blockade of both NMDA and AMPA receptors at the time of global 
ischemia prevented the increase of neurogenesis in the SGZ as well as the CA1 neuronal death . 
Neurogenesis following ischemic insult could be mediated by the glutamate-evoked increased 
levels of certain GFs, e.g. bFGF and BDNF . However, Liu et al. proposed that decrease in 
NMDA  receptor  signaling  observed  for  2  weeks  after  transient  forebrain  ischemia  can 
contribute to increase of neurogenesis in the DG (Liu et al., 1998; Westerberg et al., 1989; 
Ogawa et al., 1991). Neuronal death within the hippocampus also could provide neurogenic 
stimulus after injury .
Although increased neurogenesis in the brain in response to ischemic injury occurs, the 
majority of injury-generated neurons die early after birth . Post-injury microenvironment may 
not support the complete regeneration of the damaged area either due to significant neuronal 
injury and/or the associated inflammatory reaction .
Since only a fraction of lost neurons are actually replaced, the capacity of endogenous 
regeneration  seems  to  be  rather  limited,  making  neuroprotective  and  neurogenic  therapy 
essential to support functional recovery after cerebral ischemia . 
So far only one study have demonstrated that application of bFGF and EGF after global 
ischemia in rats gives rise to substantial regeneration of hippocampal CA1 pyramidal neurons . 
Nakatomi  et  al.  proposed  that  newly  generated  neurons  were  derived  from  the  posterior 
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periventricle (pPV), which is  adjacent to the hippocampus as a part of the LVw and contains 
precursor  cells  displaying  in  vitro stem cell  properties .  However,  the  same  therapeutical 
protocol of GF application failed to provide an increase of early neurogenesis but increased the 
infarct  volume  after  focal  ischemia  in  rats  .  Thus,  GF’s  therapeutical  effects  are  highly 
dependent on type of damage, GFs combinations, concentrations and schedule of treatment. 
1.3. Inflammation after cerebral ischemia
1.3.1. Mechanism of inflammation
Numerous mechanisms regulating cell  death,  cell  survival  and tissue regeneration are 
activated after ischemic brain injury .  One of the processes that play a role in the delayed 
progression of the damage is post-ischemic inflammation . It is characterized by activation of 
microglia, infiltration of peripheral macrophages and neutrophils into the brain initiated by local 
expression of cytokines, chemokines, and adhesion molecules . 
In the normal CNS, microglia are present in a resting state and possess a characteristic 
ramified morphology. With the onset of CNS injury, microglia become activated in association 
with a change in stellate morphology . Microglial cells are activated gaining phagocytotic and 
antigen  presenting  capacity  expressing  major  histocompatibility  complex  (MHC)  class  II 
molecules .  Microglia proliferate and migrate toward the site of injury where they remove 
debris after irreversible damage . Once activated, microglia are capable of secreting cytotoxic 
substances such as glutamate,  NO, reactive oxygen species (ROS; O2-,  H2O2,  OH.),  matrix 
metalloproteinases and their inhibitors and pro-inflammatory cytokines (TNF-α, IL-1ß and IL-
6). In the injured brain, microglia rather than astrocytes appear to be the main source of pro-
inflammatory  and  anti-inflammatory  cytokines  and  mediators  .  Astrocytes  are  far  less 
competent in presenting antigen than are microglial cells . Astrocytes express pro-inflammatory 
cytokines  and  become  ″activated″,  demonstrating  cell  hypertrophy  and  increased 
immunoreactivity for GFAP .
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Pro-inflammatory cytokines are synthesized in low levels in the normal CNS  and are 
strongly upregulated after brain insult  .  Pro-inflammatory cytokines activate inducible NOS 
(iNOS)  and  COX-2  that  regulate  the  production  of  NO,  prostaglandins  (PGs)  and  pro-
inflammatory cytokines .
NO activates a number of intracellular signaling pathways, like mitogen-activated protein 
kinases  (MAPK,  e.g.  p38  MAPK,  PKC)  and  may  ultimately  lead  to  neuronal  death  via 
inhibition of mitochondrial respiration .
Expression of COX has recently emerged as an important determinant of the cytotoxicity 
associated with inflammation  by producing superoxide and prostanoids (PGs and tromboxans) . 
COX-1 is constitutively expressed in many cell types in which it produces prostanoids that 
subserve  normal  physiological  functions.  COX-2  normally  is  not  present  in  most  cells. 
Upregulation of  COX-2 mRNA is detected in the ischemic hemisphere beginning 6h after 
ischemia  .  COX-2  reaction  products  are  responsible  for  many  of  the  cytotoxic  effects  of 
inflammation . PGs can induce the production of IL-6 by activating the p38 MAPK and PKC 
pathways  and stimulating glutamate release .
1.3.2. Anti-inflammatory mediators and treatment
Microglia activation has been proposed to be both detrimental and beneficial in certain 
disorders of neurodegeneration, inflammation, and ischemia . Phagocytosis of cellular debris 
from degenerated neurons support wound healing and neuronal regrowth, secretion of certain 
cytokines  and  GFs  can  aid  neuronal  regeneration  .  Neurotrophins  like  NGF,  BDNF  and 
neurotrophin-3 have been shown to be capable of inhibiting the MHC class II inducibility in 
microglia . Mattson et al. demonstrated suppression of glutamate-induced H2O2 by bFGF, NGF 
and  BDNF  .  These  GFs  could  increase  activity  of  superoxide  dismutases  and  glutation 
reductases,  inducing  thus  anti-oxidative  mechanisms.  Upregulation  of  macrophage  colony-
stimulating factor receptors  and triggering receptor expressed on myeloid cells-2  in activated 
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microglia has been implicated in neuroprotective microglia activity. 
While the expression of inflammatory cytokines that may contribute to ischemic injury 
has been repeatedly demonstrated,  cytokines  may also provide  ″neuroprotection″ in certain 
conditions by promoting growth, repair, and ultimately, enhanced functional recovery . Indeed, 
microglia-derived IL-1ß is required for the production of ciliary neurotrophic factor and insulin-
like growth factor 1 by astrocytes, which promote the repair of injured neurons . Moreover, on 
the model of excitotoxic injury Bernandino et al.  demonstrated a TNF-2 receptor mediated 
neuroprotective effect of TNF-α .
Inhibition of inflammation by the tetracycline derivative minocycline or non-steroidal 
anti-inflammatory drug indomethacin was neuroprotective in a model of cerebral ischemia in 
vivo . Minocycline, blocks microglia activation and proliferation through the inhibition of p38 
MAPK,  while  indomethacin  reduces  COX activity  .  Since  an  immune  response  normally 
accompanies brain injury, it  is quite possible that inflammatory molecules have a definite 
impact on the proliferative and differentiation potential of neural progenitors.
1.3.3. Inflammation and neurogenesis
The innate immune response in the brain is able to positively or negatively modulate 
neurogenesis in the CNS depending on the cytokines and GFs that are predominantly expressed 
in the cellular environment. 
Recent reports show that inflammation impairs hippocampal neurogenesis . Ekdahl and 
co-workers showed that seizure-induced neurogenesis was suppressed by lipopolysaccharide 
administration but restored by minocycline application . They presented a significant negative 
correlation between the number of new neurons and the number of activated microglia. Monje 
et al. showed that administration of indomethacin could restore the hippocampal neurogenesis 
inhibited by irradiation . IL-6, which is produced by activated microglia, was shown to play a 
key role in this mechanism . In addition, in a model of photothrombotic infarct pre- and post-
insult,  anti-inflammatory  treatment  with  indomethacin  could  increase  hippocampal 
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neurogenesis . In contrast, Sasaki et al. showed that delayed treatment with COX inhibitors 
blunted the enhanced proliferation of  neural  progenitors  in  the DG after  global  ischemia . 
Moreover,  they  observed  a  decrease  in  proliferating  cells  in  the  DG of  heterozygous  and 
homozygous COX-2 knockout mice compared to wild-type mice after ischemia. Hence the role 
of  microglia  and  inflammation  in  damage-regulated  neurogenesis  seems  to  depend  on  the 
etiology and the severity of the injury and thus requires further investigation. 
1.4. Organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures (OHC) are used for the investigation of neuronal 
damage, neuroprotection and synaptic transmission . OHC represent an  in vitro model that 
contains the different neural cell types and retains the complex three-dimensional organization 
of the nervous tissue.  Cultured slices maintain their cellular architectures and interneuronal 
connections, and neurons survive during the long-term culture and physiologically mature over 
this period, allowing an extended survival study . They contain only resident microglia and 
influx of peripheral leukocytes does not occur in this in vitro preparation. OHC provide good 
experimental access to model pathophysiological pathways in living tissues and facilitate the 
design of therapeutic agents. In particular, OHC combined with OGD could provide a surrogate 
system  for  investigation  of  neuronal  cell  loss  following  ischemic  injury  to  the  brain. 
Furthermore this system is suitable for detecting metabolism-related effects.
Little is known about neurogenesis in OHC. The topic was recently investigated in roller-
tube  and interface  OHC by Raineteau  and Kamada  .  In  roller-tube  OHC mature  granular 
BrdU/NeuN+ neurons were found in the SGZ and granular cell layer (GCL) of the DG two 
weeks  after  BrdU  application.  The  number  of  BrdU/NeuN+  neurons  corresponded  to  the 
number found in the hippocampus of adult rodents in vivo. Neurogenesis was detected in the 
DG and could be stimulated by epidermal growth factor application . In the interface OHC 
neural progenitors were identified exclusively in the suprapyramidal region of the GCL of the 
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DG. Mature BrdU/NeuN+ cells were found in the DG four weeks after BrdU application . Thus, 
it was shown that neurogenesis in OHC is limited to the DG where the newly generated neurons 
appear and maturate.
Taking together, OHC were considered as an excellent model for the in vitro investigation 
of interplay between neuronal damage, inflammation and neurogenesis in the CNS after OGD. 
This study was performed on interface OHC maintained on permeable membranes (“Stoppini 
method”)  and  all  manipulation  as  well  as  GFs  treatment  were  tested  under  serum  free 
conditions.
1.5. Aim of the project
Based on our knowledge the aim of this thesis was to investigate the pathophysiological 
events  and  neurogenesis  in  organotypic  hippocampal  slice  cultures  after  oxygen-glucose 
deprivation.
Specific aims include:
1. To identify  and  characterize  neurogenic  zones  and neural  precursors  in  OHC.  To 
characterize cell proliferation, distribution of proliferating cells in OHC under control 
conditions. To elucidate the effect of exogenous growth factors on cell proliferation 
and neurogenesis.
2. To  investigate  the  interplay  between  cell  damage,  microglia  activation,  cell 
proliferation and neurogenesis after OGD. To define the temporal relation between cell 
damage and proliferation. To elucidate the effect of exogenous growth factors on cell 
proliferation and neurogenesis after OGD.
3. To investigate  the  effect  of  inflammation  in  OGD-induced cell  damage,  microglia 
activation, cell  proliferation and neurogenesis by using anti-inflammatory treatment 
with  indomethacin  and  minocycline.  To  compare  the  effects  of  anti-inflammatory 
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compounds with effects of NMDA receptor antagonists.
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2. Materials and Methods
2.1. Materials
2.1.1. Lab instruments and materials
Amersham Pharmacia Biotech: 
Buckinghamshire, UK
 
GeneQuantpro photometer
Applied Biosystem:
(Foster City, CA, USA)
ABI PRISMTM Optical Adhesive Covers
6700 ABI PRISMTM 96-Well Optical Reaction 
Plate with Barcode (code 128)
LightCycler ABI Prism® 7000 SDS
Billups & Rothenberg, Inc.:
(Del Mar, CA, USA)
 
Modular Incubator Airtight Chamber
Bio-Rad: 
(München, Germany) 
Thermal cycler, My cycler
Campden Instruments Ltd.:
(Leicester, UK)
 
Vibratome NVSLM1
Carl Zeiss: 
(Jena, Germany)
Zeiss  LSM  5  Pascal  confocal  laser  scan 
microscopy
Axiovert 100TV transmission light microscope
Leica Instruments: 
(Nussloch, Germany)
 
Cryostat Leica CM 3050
Millipore:
(Molsheim, France)
 
0.4 µm porous Millicell membrane
Nikon : 
(Tokyo, Japan) 
Nikon Eclipse TE 300 fluorescences microscope 
The Mickle Laboratory Engineering Co.: 
(Guildford, UK) 
McIlwain tissue chopper
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2.1.2. Chemicals
Biochrom AG:
(Berlin, Germany)
1mM L-glutamine, 200 mM
0.5% gentamycine,10 mg/ml
Carl Roth GmbH + Co. KG:
(Karlsruhe, Germany)
D-(+)-Saccharose
Glycerin
Hydrochloric acid (HCl)
Paraformaldehyde
Triton X
Chemicon International, Inc.:
(Temecula, CA, USA)
bFGF
Recombinant human NGF-beta
Fermentas GmbH: 
(St. Leon-Rot, Germany)
Ribonuclease inhibitor, 40 U/µl
Invitek GmbH:
(Berlin, Germany)
50xdNTP Master Mix
Promega: 
(Madison, WI, USA)
M-MLV Reverse Transcriptase Buffer
M-MLV Reverse Transcriptase, 200 U/µl
Random Primers, 0.5ng/µl
Qiagen: 
(Hilden, Germany)
Quanti Test SYBR Green PCR Master Mix
RNeasy Mini Kit
R&D systems GmbH:
(Wiesbaden-Nordenstadt, Germany)
Recombinant human BDNF
Roche Molecular Biochemicals:
(Mannheim, Germany)
EGF, ß-urogastron
Serva:
(Heidelberg, Germany)
α-D-Glucose
Sigma:
(Deißenhofen, Germany)
3,3´-diaminobenzidine
BrdU 
Mannitol
Indomethacin
Minocycline hydrochloride
Propidium iodide (PI)
Thermo Shandon: Histomount
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Tocris Bioscience:
(Avonmouth, UK)
MK-801 (dizocilpine)
Vector Laboratories: 
(Burlingame, CA, USA) 
Phosphatase – avidin-biotin complex
Vectastain Elite ABC-kit
2.1.3. Antibodies
BD Transduction Laboratories: 
(San Jose, CA, USA)
 
Monoclonal mouse anti-Nestin
Chemicon International, Inc.:
(Temecula, CA, USA)
Monoclonal mouse anti-GFAP
Monoclonal mouse anti-neuronal nuclei (NeuN)
Dianova:
(Hamburg, Germany)
Biotinylated donkey anti-mouse
Immunologicals Direct : 
(Raleigh, NC, USA)
Monoclonal rat anti-BrdU
Jackson Immunoresearch Laboratories, 
Inc.:
(West Grove, PA, USA)
Cy3 donkey anti-mouse IgG
Cy3 donkey anti-goat IgG
Cy2 donkey anti-rat IgG 
Promega: 
(Madison, WI, USA) 
Monoclonal mouse anti-ß-III Tubulin
Santa Cruz Biotechnology: 
(Santa Cruz, CA, USA)
 
Polyclonal goat anti-doublecortin (DCX)
Serotec: 
(Oxford, UK)
Monoclonal mouse anti-OX-42
Sigma: 
(Deißenhofen, Germany)
Extra Avidin Cy3
Monoclonal rabbit anti-GFAP
Vector Laboratories: 
(Burlingame, CA, USA) 
IB4
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2.1.4. Cell culture medium and components 
Cell Concept GmbH: 
(Umkirch, Germany)
Preparation medium: 
MEM-Hanks 
25 mM Hepes
Phenol red
pH 7.35
Culture medium:
66% MEM-Hanks
33% Hanks´ balanced salt solution (HBSS)
17mM Hepes
350 mg/ml NaHCO3
5 mM glucose
pH 7.8
Gibco: 
(Eggenstein, Germany)
25% Heat-inactivated horse serum
Neurobasal-A
B27 supplement
Serum-based medium: 75% Culture meduim
1mM L-glutamine
0.5% Gentamycine10 mg/ml
25% Heat-inactivated horse serum
Serum-free medium: 75% Culture medium
1mM L-glutamine
0.5% Gentamycine
25%Neurobasal-A with 0.5% B27 supplement
2.1.5. Buffers and solutions
Ringer’s solution 124  mM  NaCl,  4.8  mM  KCl,  1.3  mM  MgSO4x7H2O,  1.2  mM 
KH2PO4, 25.6 mM NaHCO3, 2 mM CaCl2x2H2O, 10 mM glucose, 
pH 7.4
OGD-medium 124  mM  NaCl,  4.8  mM  KCl,  1.3  mM  MgSO4x7H2O,  1.2  mM 
KH2PO4, 25.6 mM NaHCO3, 2 mM CaCl2x2H2O, 10 mM glucose, 
pH 7.4
PBS 137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2PHO4,  1.4 mM KH2PO4, 
pH 7.4
TBS 99 mM Tris, 15 mM NaCl, pH 7.4
30% Sucrose 30% solution of D-(+)-saccharose in PBS
4% PFA 4% solution of paraformaldehyde in PBS
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2.1.6. Primer sequences
Gene name 5`- 3´primer sequence Primer 
concentration 
(µM)
MgCl2 
(mM)
Amplicon 
length (bp)
Accession, 
nucleotide 
number
Cyclophilin 
A
FW :AGCACTGGGGAGAAAGGATT
RW :AGCCACTCAGTCTTGGCAGT
0.05 2.5 248 NM017101  
IL-1ß FW :CACCTCTCAAGCAGAGCACAG
RW :GGGTTCCATGGTGAAGTCAAC
0.2 2.5 79 M98820  
TNF-α FW :AAATGGGCTCCCTCTCATCAGTT
C
RW :TCTGCTTGGTGGTTTGCTACGAC
0.2 3.5 269 X666539  
IL-6 FW: TCCTACCCCAACTTCCAATGCTC
RW : TTGGATGGTCTTGGTCCTTAGCC
0.2 2.5 79 M26744  
Note. FW, forward primer; RW, reverse primer; IL, interleukin; TNF-α, Tumor necrosis factor α.
2.2. Methods
2.2.1. Tissue preparation
2.2.1.1. Preparation of organotypic hippocampal slice cultures
Organotypic  hippocampal  cultures  were  prepared  according  to  the  standard  interface 
method  from postnatal  day  7-9  (P7-9)  Wistar  rats  (Harlan  Winkelmann GmbH Borchen, 
Germany).  After  decapitation,  the  brain  was  removed,  hippocampi  were  dissected  and 
transversely sliced into a 350 µm thickness on a McIlwain tissue chopper. The slices were then 
carefully separated with two pairs of fine forceps and transferred to sterile, 0.4 µm porous 
Millicell membrane, using a glass Pasteur pipette. Slices were maintained in culture at 370C in 1 
ml of serum-based medium for 2-3d. Thereafter cultures were transferred to serum-free medium 
and kept in a tissue culture incubator for 12d at 330C in 5% CO2 with medium change twice a 
week. 
OHC were selected with PI before the experiment to exclude damaged cultures. PI was 
added to the culture medium in final concentration of 2 µg/ml for 12h. PI negative OHC were 
selected using fluorescence microscopy. 
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2.2.1.2. Preparation of organotypic cortex-hippocampal cultures 
OCC were prepared from P7-9 Wistar rats using a modification of the method by Plenz 
and Kitai  .  After decapitation,  the brain was removed and placed into a  sterile  Petri  dish. 
Coronal sections of 400 µm were cut using a vibratome and dissected to dorso-lateral cortical 
and  hippocampal  tissues  (Fig.  2.1).  Slices  were  plated  onto  Millicell  culture  inserts  and 
maintained for 10d under the same conditions as OHC.
Fig. 2.1. Schematic drawing of a rat brain coronal section demonstrating the anatomy of OCC.
2.2.2. Oxygen and glucose deprivation
OGD was used as an  in vitro model of cerebral ischemia. For OGD,  the inserts with 
OHC were placed into 1ml of Ringer solution containing mannitol (10mM) instead of glucose 
(OGD-medium)  in sterile 6-well culture plates. Before use,  OGD-medium was saturated by 
flushing a gas mixture of 95% N2/5% CO2 for 10 min. The cultures were then placed into an 
airtight chamber and exposed to 10 min of 95% N2/5% CO2 gas flow. After that the chamber 
was sealed and placed for 40 min in an incubator where the temperature was maintained at 
370C. Control cultures were maintained for the same time under normoxic atmosphere in 
glucose-containing Ringer’s solution. After OGD, OHC were returned to their original culture 
conditions.
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2.2.3. Experimental setups
2.2.3.1. Cell proliferation and neurogenesis in OHC
OHC  were  prepared  from  P7-9  Wistar  rats  and  maintained  in  Millicell  semiporous 
membrane for 12-14d. Slices were selected using PI before proliferating cells were labeled 
by treatment with 20µM BrdU for 2d (Fig. 2.2). BrdU+ cells were detected at 1d, 3d, 6d and 
10d after BrdU was applied first. BrdU/DCX+ cells were detected at 3d and 6d, BrdU/ß-III 
Tubulin+ cells at 6d and 10d and BrdU/NeuN+ cells at 10d.
2.2.3.2. Growth factor treatment 
OHC were treated with GF to a final concentration of BDNF 25 ng/ml, bFGF 5 ng/ml; 
EGF 10 ng/ml or NGF 10 ng/ml for 2d or 5d (Fig. 2.2). GF was added 24h after the start of 
BrdU application. BrdU+ cells were detected at 3d and 6d after BrdU was applied first. BrdU/ß-
III Tubulin+ cells were detected at 6d. For bFGF neurogenesis was assessed also at 3d with 
BrdU/DCX immunohistochemistry.
Fig. 2.2. Experimental setup used to investigate basal and GF modulated proliferation and neurogenesis in OHC. 
2.2.3.3. Cell damage, microglia, cell proliferation and pro-inflammatory cytokines after 
OGD
To study the temporal profile of cell damage, microglia activation, cell proliferation and 
pro-inflammatory cytokine levels early after insult, OHC were subjected to analysis at 0, 2, 6, 
16 and 24h after OGD (Fig. 2.3).
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Fig.  2.3.  Experimental  setup  used  to  study  temporal  profile  of  neuronal  damage,  microglia  activation,  cell 
proliferation and pro-inflammatory cytokines mRNA level after OGD. 
PI and BrdU were added to the OGD-medium to a final concentration 2 µg/ml and 20 µM 
respectively and were present during OGD. Furthermore, cultures were incubated under normal 
conditions with PI (2 µg/ml) and BrdU (20 µM) containing medium. PI uptake was assessed at 
0,  2,  6,  16  and  24h  after  OGD. Thereafter  OHC  were  fixed,  cryosected  and 
immunohistochemically stained for microglia and proliferating cells detection. Damage was 
assumed as an integral density of PI uptake in the CA1 or DG. OX-42+ and BrdU+ cells were 
quantified in the CA1 and DG areas. IL-1ß, TNF-α and IL-6 mRNA levels were assessed by 
real-time RT-PCR using SYBR green. Total RNA was isolated from the OHC at 2, 4 or 8h after 
OGD. As a house-keeping gene peptidylprolyl isomerase A (cyclophilin A) was detected.
2.2.3.4. Cell proliferation and neurogenesis after OGD
To investigate neurogenesis in OHC after insult, slices were incubated with BrdU for 2d 
after OGD (Fig. 2.4). Early neurogenesis was detected at 3d with BrdU/DCX immunostaining, 
late neurogenesis at 6d with BrdU/DCX and BrdU/ß-III Tubulin labeling.
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Fig. 2.4. Experimental setup used to study cell proliferation and neurogenesis after OGD and with or without 
growth factors treatment.
2.2.3.5. Growth factor treatment after OGD
To study how the exogenous GFs can influence OHC regulated cell  proliferation and 
neurogenesis, GF was added into the culture medium in a final concentration of BDNF 25 
ng/ml, bFGF 5 ng/ml, EGF 10 ng/ml or NGF 10 ng/ml for 2d or 5d in 24h after OGD 
(Fig. 2.4). BrdU+ cells were detected at 3d and 6d after OGD. BrdU/ß-III Tubulin+ cells 
were detected at 6d after 5d of bFGF treatment.
2.2.3.6. Anti-inflammatory compounds treatment
To investigate the contribution of inflammation in neuronal damage, cell proliferation, 
microglia activation and neurogenesis, OHC were treated with indomethacin or minocycline 
hydrochloride.  Compounds were added to  the culture  medium at  a  final  concentration of 
10µM or 50µM for 2h before, during, and 2d after OGD. Since indomethacin was dissolved 
in ethanol, the appropriate vehicle-control (0.1% ethanol) was included. As a positive control, 
the well known NMDA-receptor antagonist MK-801 (10µM) was used. OHC were treated 
with BrdU immediately after OGD for 2d. Neuronal damage and microglia were detected 24h 
after OGD, proliferating cells and newly generated BrdU/DCX neurons were defined at 6d.
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Fig. 2.5. Experimental setup used to investigate the role of inflammation in neuronal damage, cell proliferation and 
neurogenesis. IN, indomethacine; MI, minocycline.
2.2.4. Cell damage
Cell damage was evaluated by cellular uptake of PI. The fluorescent dye intercalated into 
the  DNA of  cells  that  lost  membrane  integrity  and  therefore  represents  a  marker  of  cell 
degeneration. OHC were incubated with PI (10µM) for 2h before measurement. To follow after 
the temporal changes of cell damage after OGD PI uptake was measured at 1d, 5d, 10d and 15d. 
For  PI  intensity  detection  slices  were  excited  with  a  510–560  nm  light  and  the  emitted 
fluorescence  acquired  at  610  nm  using  a  rhodamine  filter  on  an  inverted  fluorescence 
microscope (Eclipse TE 300). Images were taken using a CCD camera and analyzed using 
image analysis  software  (LUCIA, Nikon).  Damage was given as  an integral  density  of  PI 
intensity in the area.
2.2.5. Immunohistochemistry
2.2.5.1. Microglia 
Microglia were detected by immunolabeling of CD11b/c surface receptors - OX-42, 
which are complement receptors type 3. Although CD11b/c is one of the earliest markers to be 
upregulated on activated microglia, it  is also expressed in resting microglia . Cultures were 
fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS, pH 7.4) for 40 min. 
After 24h incubation with 30% sucrose, OHC were cryosectioned in 20µm coronal slices. After 
endogenous peroxidase quenching with 0.6% peroxide hydrochloride slices were washed with 
tris-buffered saline (TBS). Thereafter the nonspecific binding was blocked with 10% donkey 
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normal  serum  (DNS)  and  0.5%  Triton-X  in  TBS  for  4h  at  room  temperature  (RT). 
Subsequently,  slices  were  incubated  with  primary  antibody monoclonal  mouse  anti-OX-42 
(1:100) in blocking solution overnight at 40C. The slices were rinsed with TBS, incubated with 
the secondary antibody biotinylated donkey anti-mouse (1:500) for 1h, and reacted with alkaline 
phosphatase – avidin-biotin complex (1:400) and 3,3´-diaminobenzidine. After washing, slices 
were  left  to  dry  and  coverslipped  with  histomount.  Microglia  were  quantified  using  the 
transmission light microscope (Zeiss) and Axiovision Software (Zeiss).
2.2.5.2. Proliferating cells
Proliferating  cells  were  detected  by  using  the  DNA  replication  marker 
bromodeoxyuridine (BrdU), a thymidine analog which incorporates into the DNA of all cells 
during  the  S-phase  of  cell  cycle  .  OHC  were  incubated  with  BrdU  (20µM).  Fixed  and 
cryosectioned slices were used for immunohistochemistry. DNA denaturation was achieved by 
treatment with 2N HCl at 36°C for 60 min. Slices were rinsed with PBS and incubated with 
10% DNS and Triton-X 0.5% in PBS for 3h, at  RT, thereafter with rat  anti-BrdU (1:300) 
primary antibody overnight at 4°C. BrdU+ cell were visualized by Cy2 donkey-anti rat IgG 
(1:500). Slices were washed and coverslipped with PBS-Glycerin (2:3).
2.2.5.3. Newly generated neurons
To determine the fate of newly generated neurons the following neuronal markers were 
chosen: the early neuronal markers DCX, ß-III Tubulin and the mature neuronal marker NeuN 
(see Tab. 2.1). OHC at age 12-14DIV were incubated for 2d in medium containing 20µM 
BrdU. Cultures were washed then with PBS and fixed at 1d, 5d or 10d post-treatment. After 24h 
incubation with 30% sucrose and freezing,  cultures were cryosectioned and 20µm coronal-
sectioned slices were used for immunodetection. DNA denaturation was achieved by treatment 
with 2N HCl at 36°C for 60 min. Thereafter OHC were incubated for 3h with blocking solution 
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(10% normal serum, 0.5% Triton X-100 in PBS) and overnight with rat monoclonal anti-BrdU 
IgG2a and an antibody against DCX or ß-III Tubulin or NeuN in PBS containing 5% normal 
serum and 0.5% Triton X-100 at 4°C. Slices were incubated for 2h at room temperature with 
Cy2 donkey anti-rat IgG (1:500) and Cy3 donkey anti-goat IgG (1:500) for BrdU/DCX+, Cy2 
donkey anti rat IgG (1:500) and Cy3 donkey anti mouse IgG (1:500) for BrdU/ß-III Tubulin and 
BrdU/NeuN, then washed with PBS and coverslipped. Controls included omission of both or 
one of the primary antibodies.
                   Table 2.1. Cell specific markers used for immunohistochemistry.
Primary antibody Dilution Cell type
Monoclonal rat anti-BrdU 1:300 proliferating cells
Monoclonal mouse anti-Nestin 1:500 astrocytes, precursor cells
Monoclonal mouse anti-GFAP 1:500 astrocytes
Monoclonal rabbit anti-GFAP 1:500 astrocytes
Polyclonal goat anti-DCX 1:300 neuroblasts
Monoclonal mouse anti-ß-III Tubulin 1:1000 immature neurons
Monoclonal mouse anti-NeuN 1:1000 mature neurons
IB4 1:40 microglia
2.2.5.4. Other cell types
To characterize the different cell types present in OHC, double and single 
immunolabeling of unsectioned, coronal- or cross-sectioned slices was performed using the 
following cell markers: GFAP, Nestin, DCX, ß-III Tubulin, NeuN, BrdU (see Tab. 2.1). As 
secondary  antibodies  Cy2  or  Cy3  donkey  anti-mouse  IgG and  Cy3  donkey  anti-goat  IgG 
(1:500) were used. Microglia were detected with IB4 and visualized with Extra Avidin Cy3 
(1:500). 
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2.2.6. Isolation of RNA 
Total RNA was isolated from OHC with the total RNA isolation kit (RNeasy) from 
Qiagen. Briefly, the slices were transferred one by one into the 1.5 ml tube with a brush (from 
3 to 6 slices per group) and disrupted in 350 µl Buffer RLT with a pestle. One volume of 70% 
Ethanol was then added, 700 µl of sample was applied to an RNeasy mini spin column in a 2-
ml collection tube, and centrifuged for 15 sec at 10,000 x g. Thereafter 700 µl of Buffer RW1 
was pipeted onto the RNeasy column, and centrifuged for 15 sec at 10,000 x g for washing. 
RNeasy column was transferred into a new 2-ml collection tube, 500 µl Buffer RPE was 
pipeted onto the RNeasy column, and centrifuged for 15 sec at 10,000 x g for washing. After 
the second washing with 500 µl Buffer RPE, the RNeasy column was centrifuged for 2 min at 
maximum speed to dry the RNeasy membrane. The RNeasy column was then transferred into 
a new 1.5-ml collection tube, 50 µl RNase-free water was pipeted onto the RNeasy membrane 
and centrifuged for 1 min at 10,000 x g to elute RNA contained solution. DNase digestion 
was made using the RNase-Free DNase set (Qiagen). For that 5 µl of RNase-free Buffer and 1 
µl RNase-free DNaseI were added to the tube with RNA and incubated for 1h at 370C. The 
rest of DNaseI was removed by incubation with DNase inactivation reagent for 2 min at RT. 
After  centrifugation  at  10,  000 x g for  1  min  the supernatant  containing total  RNA was 
transferred  to  the  RNA-free  tube  and  stored  at  –800C.  Before  use  in  experiment  RNA 
concentration was measured at a wavelength 260 nm using a photometer.
2.2.7. Real-time reverse transcription polymerase chain reaction (real time RT-PCR)
For real time RT-PCR not PI-treated OHC were used. 
RNA was reverse-transcribed as follows:
0.5 ng/µl random primers 1 µl
Template RNA (1 µg) 15 µl
↓ 700C, 5 min
add
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M-MLV Reverse Transcriptase Buffer x5 5 µl
M-MLV Reverse Transcriptase 1 µl
Ribonuclease Inhibitor 0.6 µl
dNTP Master Mix 1 µl
RNAse free water 1,4 µl
↓ 370C, 1h
Store cDNA at +40C 
cDNA  was  amplified  using  the  primers  based  on  rat  peptidylprolyl  isomerase  A 
(cyclophilin A), rat IL-1ß, rat IL-6 and rat TNF-α sequence. The probe without template 
served as a negative control. 
PCR was carried out with Quanti Test SYBR Green PCR Master Mix (Qiagen) using 200 
ng of cDNA in each reaction. Briefly, quantitative PCR was performed using LightCycler ABI 
Prism® 7000 SDS. PCR conditions for amplifications were: denaturation for 15 min at 950C; 40 
cycles at 950C for 30 sec, 550C for 30 sec and 720C for 1 min. Amplification specificity was 
analyzed using a melting curve and by TBE agarose (1,5 %) gel electrophoresis using ethidium 
bromide.  Documentation  was  done  by  a  still  video  system.  Results  were  analyzed  using 
LightCycler Software v. 2.0 (Applied Biosystems) after establishing a reaction efficiency for 
each  pair  of  primers.  Quantification  was  carried  out  using  ∆CT method.  The  results  are 
presented as relative increase (folds) compared to control.
2.2.7. Cell quantification and statistical analysis
Image analysis of BrdU and double immunofluorescent labeling was performed by Zeiss 
LSM 5 Pascal confocal laser scan microscopy (Zeiss, Jena, Germany) with excitation/emission 
wavelengths  of  535/565  nm (Cy3,  red)  and  470/505  nm (Cy2,  green).  BrdU+ cells  were 
quantified in the areas CA1 (0.24 mm2; 6 squares of 0.04 mm2), CA3 (0.16 mm2; 4 squares of 
0.04mm2) or DG (0.24 mm2; 6 squares of 0.04 mm2) in cryosectioned slices (Fig. 2.6).
Doublelabeled neurons were quantified in one confocal plane throughout the area CA3, 
CA1, DG or the pPV. Based on the BrdU staining pattern (evenly stained BrdU+ nucleus vs 
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punctuated) neurons detected in the stratum oriens and glial envelope (GE) were considered to 
be derived from the pPV and thus were included in the pPV group. Doublelabeling was proven 
using the z-stack analysis and Prizma Colocalization software (Zeiss).
Fig. 2.6. Schematic drawing of BrdU+ cells quantification in OHC. 
All data are given as the mean±SD. Experiments were repeated at least three times. The 
statistical significance of differences between means was evaluated by ANOVA followed by 
post-hoc Newman-Keuls test for multiple comparison, with P<0.05 considered significant.
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3. Results
3.1. Characterization of OHC
3.1.1. Identification and in situ distribution of CNS cell types in OHC
OHC  were  prepared  from  P7-9  Wistar  rats  and  cultivated  for  two  weeks  before 
experiments were performed. To characterize the three-dimensional structure of OHC, different 
cell types were detected by immunohistochemistry in unsectioned (“whole mounts”) and cross-
sectioned  12-14  DIV  slices.  Astrocytes  (GFAP+),  precursor  cells  (Nestin+),  migrating 
neuroblasts (DCX+), young and mature neurons (ß-III Tubulin+), mature neurons (NeuN+) and 
microglia (IB4+) were labeled by the respective markers. Images were taken in different regions 
of OHC (Fig. 3.1A). During cultivation OHC flattened down from an original 350 µm to about 
150-180 µm. A glial  envelope (GE) had formed, which ensheathed the slice and probably 
functioned as a protective layer (Fig. 3.1B, 3.1B´). The 4-7 µm GE cell layer contained GFAP+ 
and GFAP/Nestin+ astrocytes, and Nestin+ cells with stellar morphology. These cells were 
evenly scattered on the top of slice surface (Fig. 3.1C) and formed a dense network at the 
“OHC–culture membrane border” (Fig. 3.1.D). There were also numerous microglia present in 
the GE. The majority of microglia had the rounded morphology of activated cells (Fig. 3.1E) 
while inside the slice mostly ramified microglia could be observed (Fig. 3.1F). Morphologically 
different Nestin+ cell populations could be detected in OHC: (1) relatively small cells (6-9 µm) 
with stellar morphology located in the GE and the molecular layer (ML; Fig. 3.1C, D, G), (2) 
larger Nestin+ cells (13-16µm) in the DG (Fig. 3.1G) and (3), Nestin+ elongated cells (8-9 µm; 
Fig. 3.1H, green). This third type of Nestin+ cells formed the border between the stratum oriens 
and the GE. Interestingly, immature DCX+ (Fig. 3.1H, red) or DCX/ß-III Tubulin+ (Fig. 3.1I) 
neurons were also found here. Mature neurons (NeuN+) formed the pyramidal cell layer or 
were occasionally distributed randomly in the stratum oriens (Fig. 3.1J). However NeuN+ cells 
were not observed at the “stratum oriens-GE border”.
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Fig. 3.1. Identification and in situ distribution of CNS cell types in OHC. Transmission light image of 14 
DIV OHC (A). Different cell types were detected by immunohistochemistry in unsectioned (“whole mounts”) 
and cross-sectioned 14 DIV slices. The ß-III Tubulin/GFAP (ß-III Tubulin – red; GFAP - green) staining image 
(B)  and  schematic  drawing  (B´)  show the  GE ensheathing  the  ß-III  Tubulin+  hippocampal  slice.  The  GE 
contains GFAP, GFAP/Nestin+ astrocytes and Nestin+ cells on the surface of the slice (C; Nestin – red; GFAP - 
green) and at the “OHC–culture membrane border” (D). Activated microglia in the GE (E) and resting microglia 
inside of the slice culture (F). Smaller Nestin+ cells with stellar morphology in the ML (G, arrow head) and 
larger Nestin+ cells in the DG (G, arrow). Elongated Nestin+ cells (green) and DCX+ neuroblasts (red) at the 
“stratum oriens-GE border” (H). DCX+ neuroblasts (red) expressed ß-III Tubulin (green) at the “stratum oriens-
GE border” (I, arrow). Mature NeuN+ cells in the pyramidal cell layer and stratum oriens (J). Scale bar 200µm 
for B; 100µm for G; 20µm for D, E, H, I, J; 10µm for C and F.
3.1.2. Distribution and appearance of proliferating cells in OHC
To investigate proliferation in OHC, dividing cells were labeled with 20µM BrdU for 2d 
(see Fig. 2.2). Single BrdU immunohistochemistry revealed massive cell proliferation in the GE 
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(surface of the slice; Fig.  3.2A) compared to low proliferation inside the slice (Fig.  3.2B). 
BrdU+ cells were quantified in 20µm cryosectioned slices at 1d, 3d, 6d and 10d after BrdU 
application. Massive increase in cell proliferation was found at 3d compared to 1d after BrdU 
was first applied (Fig. 3.2C). The number of proliferating cells did not change significantly 
from 3d to 6d or from 6d to 10d of incubation. The relatively high level of basal proliferation 
detected in OHC was probably due to the young age of the tissue at the time of preparation (P7-
9).
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Fig. 3.2. Distribution and quantification of proliferation in OHC. OHC were treated with BrdU for 2d thereafter 
proliferating cells were detected by immunohistochemistry. Images show massive cell proliferation in the GE (A) 
compared to the inner layers of OHC (B). (C) Proliferating cells were quantified in 20µm sectioned slices at 3d, 6d 
and  10d  after  BrdU  application.  BrdU,  bromodeoxyuridine;  CA,  cornu  ammonis;  DG,  dentate  gyrus;  ML, 
molecular layer. Scale bar 200µm for A and B.
3.1.3. Cell proliferation and growth factor treatment 
Next we choosed to examine the effect of several GFs on cell proliferation. OHC were 
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treated with BDNF (25 ng/ml), bFGF (5 ng/ml), EGF (10 ng/ml) or NGF (10 ng/ml) for 2d 
or 5d (see Fig. 2.2). 
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Fig. 3.3. Effect of GF treatment on cell proliferation in OHC. OHC were treated with one of the following GF in 
a final concentration of BDNF 25 ng/ml, bFGF 5ng/ml, EGF 10 ng/ml or NGF 10ng/ml for 2d or 5d. GF was added 
into the culture medium 24h after the start of BrdU treatment. BrdU+ cells were quantified at 3d and 6d in the DG 
(A) and in the CA1 area (B). “*” represents the significant differences in number of BrdU+ cells between 2d and 5d 
GF treatment, “#” represents the significant differences in number of BrdU+ cells between control and GF-treated 
grous.The data are expressed as the mean±SD, *P<0.05; **P<0.01; ***; ###P<0.001 (ANOVA followed by post-hoc 
Newman-Keuls test).
Proliferating cells were detected at 3d (2d treatment) or 6d (5d treatment) after BrdU was 
first applied. BDNF, bFGF or NGF applied for 2d failed to increase cell proliferation in the 
DG (Fig. 3.3A) or CA1 whereas short EGF treatment stimulated proliferation in the CA1 
(Fig. 3.3B). The number of BrdU+ cells was significantly increased in both areas by longer 
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treatment (5d) with bFGF (Fig. 3.3). Other factors did not change the proliferation pattern 
neither in the DG nor in the CA1. The differences in cell proliferation between short and 
long GF application were found. bFGF applied for 5d could enhance proliferation compared 
to shorter bFGF treatment (2d). In contrast, long EGF application resulted in reduction in 
number of BrdU+ cells seen at 3d. Thus, from the several GFs used here only bFGF and 
EGF could show the time-dependent mitogenic properties under control conditions. Next 
we investigated neurogenesis in OHC.
3.2. Neurogenesis in OHC
3.2.1. Identification of a second neurogenic zone in OHC
In order to identify 1) whether the immature neurons (DCX+ and/or ß-III Tubulin+) 
located  at  the  border  between  the  stratum  oriens  and  the  GE  originated  from  the  LVw 
precursors  and  2)  whether  these  precursors  appeared  only  after  trauma  (separation  of 
hippocampi during preparation) or also in the absence of injury combined cortex-hippocampal 
organotypic slice cultures (OCC) were prepared (see Fig. 2.1). These cultures contained the 
hippocampus, the cortex and the intact posterior part of the LVw, where the precursor cells 
could be located (Fig. 3.4A). Nestin+ or BrdU/DCX+ cells were detected at 3d and BrdU/ß-III 
Tubulin+ cells at 6d after BrdU application. Although Nestin+ cells were scattered throughout 
the slice  culture,  above the stratum oriens  they formed a  defined structure appearing as a 
borderline between the dorsal hippocampus and the cortex (Fig. 3.4B), thus resembling the 
“stratum oriens-GE border” in OHC. This structure is the pPV, part of the LVw, which lines the 
hippocampus and contains elongated Nestin+ cells (Fig. 3.4C). DCX+ cells in the pPV and in 
the DG could be detected in OCC (Fig. 3.4D).
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Fig. 3.4. Neurogenesis in OCC. OCC were prepared form P7-9 rats. 10 DIV OCC were treated with BrdU 
thereafter Nestin and BrdU/DCX immunohistochemistry was performed at 3d and BrdU/ß-III Tubulin at 6d after 
BrdU application. (A) Transmission light image of OCC. Nestin immunohistochemistry showing the pPV at the 
“cortex–hippocampus border” (B, arrow). The box in B is magnified in C demonstrating the elongated Nestin+ 
cells (arrow) in the pPV. DCX (red) immunoreactivity in the DG and the pPV (D, arrows). ß-III Tubulin staining 
(E,  red)  showing  the  pPV  (arrow)  between  hippocampus  and  cortex.  The  box  in  E  is  magnified  in  F 
demonstrating the BrdU/ß-III Tubulin+ neurons (arrows; BrdU – green; ß-III Tubulin – red) in the dorso-lateral 
part of the pPV at 6d after BrdU application. Scale bar 200µm for B, D and E; 20µm for F; 10µm for C.
Moreover the intensity of DCX immunoreactivity was stronger in the pPV compared to the DG. 
Since LV was mostly ß-III Tubulin negative, it appeared as a gap between hippocampus and 
cortex (Fig. 3.4E). Newly generated neurons (BrdU/DCX+ or BrdU/ß-III Tubulin+) could be 
detected at the dorso-lateral part of the pPV (Fig. 3.4E, square). BrdU/DCX+ cells found 3d 
after BrdU application seemed to be isolated from each other (data not shown), whereas at 6d 
many BrdU+ cells expressed ß-III Tubulin and formed groups of ß-III Tubulin+ cells (Fig. 
3.4F). 
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Fig. 3.5. The pPV as a neurogenic zone in OHC. ß-III Tubulin/GFAP and Nestin/GFAP immunohistochemistry 
was performed in 14 DIV cross sectioned OHC. (A) Schematic drawing of cross sectioned OHC and the location of 
the pPV. The pPV was the ß-III Tubulin negative structure (B, arrow; ß-III Tubulin – red; GFAP - green) at the 
“CA1 side” which was not present at the “DG side” (C) of OHC. Nestin+ cells (red) in the pPV (D). The region in 
the box in D is shown at a higher magnification in E demonstrating the elongated morphology of Nestin+ cells in 
the pPV. Nestin+ cells with stellar morphology in the GE at the “DG-side” (F; Nestin – red; GFAP - green). Scale 
bar: 20µm for B, C, D, F; 10µm for E.
Thus, in OCC of P7-9 rats, the pPV lining the hippocampus contained Nestin+ precursors, 
DCX+ neuroblasts and newly generated ß-III Tubulin+ neurons. Similar to OCC the pPV could 
be also identified in OHC as a mostly ß-III Tubulin negative area at the dorsal part of the culture 
(“CA1-side”; Fig. 3.5A) as demonstrated by ß-III Tubulin/GFAP staining (Fig. 3.5B). This 
structure was not present at the ventral part of the culture (“DG-side”; Fig. 3.5C). Elongated 
Nestin+ cells probably originating from the pPV were present in this structure (Fig. 3.5D, E). At 
the “DG-side” only Nestin+ cells with stellar morphology and Nestin/GFAP+ cells from the GE 
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could be observed (Fig. 3.5F). These data showed that in addition to the DG the pPV represents 
a second neurogenic zone in OHC. Since Nestin+ precursors in the pPV and the DG had a 
different morphology, we investigated whether there were also functional differences.
3.2.2. Qualitative comparison of neurogenesis in the DG and the pPV of OHC
Next,  the  basal  neurogenesis  in  the  two  neurogenic  zones  identified  in  OHC  was 
compared.  Newly  generated  neurons  were  detected  at  different  time  points  after  BrdU 
application by the early neuronal marker DCX (3d and 6d) or ß-III Tubulin (6d and 10d). DCX 
labeling of OHC was predominant in the GCL of the DG (Fig. 3.6A). However some DCX+ 
cells were also found in the pyramidal cell layer, stratum oriens and at the “stratum oriens-GE 
border”. These cells probably originated from pPV precursors.
3.2.2.1. Neurons generated in the DG assumed a granular cell morphology and showed 
mostly a punctuated nuclear BrdU pattern 
BrdU/DCX+ neurons could be found in the DG at 3d after BrdU application (Fig. 3.6B). 
BrdU/DCX+ cells were located mostly in the SGZ however some cells were observed in the 
hilus where they assumed the morphology of migrating neuroblasts (Fig. 3.6C). 
The BrdU staining in the majority of doublelabeled neurons appearing in the DG showed 
a punctuated pattern in the BrdU+ nuclei. At 6d after BrdU application BrdU/ß-III Tubulin+ 
neurons with a granular cell morphology in the GCL were detected (Fig. 3.6D). These cells 
were also found later on at 10d (Fig. 3.6E). Very few newly generated neurons which expressed 
the mature neuronal marker NeuN at this time point were observed in the DG (Fig. 3.6F).
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Fig. 3.6. Neurogenesis in the DG of OHC. After 2d BrdU treatment of 14 DIV OHC, newly generated neurons 
were  detected  by  DCX  at  3d  and  6d  or  ß-III  Tubulin  at  6d  and  10d  after  BrdU  application.  (A)  DCX 
immunoreactivity in OHC. Arrows indicate DCX+ cells at the “stratum oriens-GE border”. BrdU/DCX+ cells in 
the SGZ of the DG at 3d (B, arrow; BrdU – green; DCX - red). Note the punctuated pattern of BrdU labeled nuclei 
of newly generated neurons in the DG. Migrating BrdU/DCX+ neurons in the hilus at 6d (C, arrow). BrdU/ß-III 
Tubulin+ neurons in the GCL of the DG at 6d (D, arrow) and 10d (E, arrow; BrdU – green; ß-III Tubulin – red). 
Mature BrdU/NeuN+ neuron in the DG at 10d (F, arrow; BrdU – green; NeuN – red). Scale bar: 200µm for A; 
10µm for E; 5µm for B, C, D and F.
3.2.2.2. Neurons from pPV were present in the pPV and the stratum oriens and had 
evenly stained BrdU+ nuclei 
In the pPV BrdU/DCX+ cells were observed at an early (3d) and later time point (6d). 
They were found in the stratum oriens (Fig. 3.7A, B) or in the pPV (Fig. 3.7C). At 6d BrdU/ß-
III Tubulin+ cells with  neuroblast morphology were also detected in the pPV  (Fig. 3.7D) or 
stratum oriens (Fig. 3.7E). The BrdU staining pattern of the nucleus DCX+ neurons generated 
in the pPV differed from the one in the DG. In the majority of newly generated neurons in the 
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pPV the BrdU labeling was not punctuated, but the whole nucleus was evenly stained. Only few 
newly generated neurons with a punctuated BrdU staining pattern were found here (data not 
shown). This criterion was essential to differentiate between DG and pPV derived neurons. At 
10d BrdU/ß-III Tubulin+ cells showed a different morphology ranging from round neuroblasts 
with or without cell processes to developing neurons (Fig. 3.7F).
Fig. 3.7. Neurogenesis in the pPV of OHC. 14 DIV OHC were treated with BrdU for 2d thereafter newly 
generated neurons were detected by DCX at 3d and 6d or ß-III Tubulin at 6d and 10d after BrdU application. 
BrdU/DCX+ neurons in the stratum oriens at 3d (A, arrow) and at 6d (B, arrow; BrdU – green; DCX – red). 
BrdU/DCX+ neurons in the pPV at 6d (C, arrow). Note the even pattern of BrdU labeling of the nuclei of 
newly generated neurons in the pPV. BrdU/ß-III Tubulin+ neurons with neuroblast morphology in the pPV (D, 
arrow; BrdU – green; ß-III Tubulin – red) and the stratum oriens at 6d (E, arrow). BrdU/ß-III Tubulin+ neurons 
with neuroblast or migrating phenotype in the pPV (F, arrows). Scale bar: 20µm for E, F; 10 µm for A; 5µm 
for B, C and D.
Since BrdU/ß-III Tubulin staining included the whole neuronal cell body and processes, 
differences in the size of newly generated neurons (data not shown) could be also observed. The 
majority of neurons seen were small and could be defined as interneurons. However numerous 
large, “pyramidal-cell like” neurons (15µm) were also found close to the stratum oriens.
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3.2.3. Quantitative comparison of neurogenesis in the DG and the pPV
To compare  neurogenesis  in  the  two  neurogenic  regions  of  OHC,  BrdU/DCX+ and 
BrdU/ß-III Tubulin+ neurons were quantified in DG, CA1, CA3 and pPV area at 3d, 6d and 
10d  after  BrdU  application.  Based  on  the  BrdU  staining  pattern  (evenly  stained  BrdU+ 
nucleus), neurons appearing in the stratum oriens and the GE were counted as pPV-derived 
cells.  The number  of  newly generated neurons in  the DG did not  increase from 3d to  6d 
(BrdU/DCX)  or  from  6d  to  10d  (BrdU/ß-III  Tubulin)  (Fig.  3.8).  A  slight  decrease  of 
BrdU/DCX+ cells from 3d to 6d in newly generated neurons was observed. In comparison to 
the  DG  the  pPV  contained  more  BrdU/DCX+  neurons  at  3d  however  their  number  also 
decreased from 3d to 6d (Fig. 3.8).
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Fig. 3.8. Quantitative analysis of basal and bFGF-induced neurogenesis in OHC.12-14 DIV OHC were treated 
with BrdU for 2d thereafter newly generated neurons were detected with DCX at 3d and 6d or with ß-III Tubulin at 
6d and 10d after BrdU application. The data are expressed as the mean±SD, ** P <0.01 and ***P<0.001 (ANOVA 
followed by post-hoc Newman-Keuls test). 
A significant increase of neurogenesis (BrdU/ß-III Tubulin) in the pPV was observed at 10d in 
comparison to 6d. A rather low basal neurogenesis was observed in the DG vs the pPV. We 
hypothesized that this difference could be indicative of a functional difference between the two 
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populations of precursors. Therefore we wanted to compare the response to the exogenous 
neurogenic stimulus - GFs.
3.2.4. The DG and the pPV precursors showed a different response to growth factor 
treatment
The neurogenic properties of DG and pPV precursors were investigated by the application 
of  GFs  . The  neurogenic  response  to  GFs,  survival  and  development  of  newly  generated 
neurons was detected after longer (5d) GF treatment by BrdU/ß-III Tubulin labeling (see Fig. 
2.2). GFs failed to alter neurogenesis in the DG (Fig. 3.9A). bFGF could increase the number of 
BrdU/ß-III Tubulin+ neurons in the pPV whereas EGF treatment resulted in significant decrease 
of neurogenesis in this zone. BDNF or NGF application did not change the basal neurogenesis 
in the pPV. 
Since only bFGF showed the significant  neurogenic effect  in our system, we further 
studied the influence of short (2d) and long (5d) bFGF treatment on neurogenesis and migration 
of newly generated neurons in the CA1 and CA3 pyramidal layers. A fast neurogenic response 
to bFGF after  2d treatment in the DG (P=0.109; control vs bFGF) and in the pPV with a 
significant increase of neurogenesis in the pPV was found (Fig. 3.9B). Later on (5d treatment) 
lower numbers of newly generated neurons (BrdU/ß-III Tubulin) were found in both neurogenic 
zones. At this time point a neurogenic effect was still observed in the pPV while in the DG the 
number of newly generated neurons (BrdU/ß-III Tubulin) was decreased and not different from 
the untreated control.
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Fig. 3.9. Quantitative analysis of GF-regulated neurogenesis in OHC. (A) Effect of long (5d) GF treatment 
on neurogenesis in the DG and pPV. GF was added into the culture medium in 24h after BrdU was applied first 
in a final concentration of BDNF 25 ng/ml, bFGF 5ng/ml, EGF 10 ng/ml; NGF 10 ng/ml for 5d. (B) Effect of 
short (2d) and long (5d) bFGF treatment on neurogenesis and cell migration in OHC. OHC were treated with 
bFGF for 2d (short treatment) and 5d (long treatment). Newly generated neurons were detected at 3d by DCX 
and at  6d by ß-III  Tubulin.  The data are expressed as  the mean±SD, *P <0.05 and ***P<0.001 (ANOVA 
followed by post-hoc Newman-Keuls test). 
In the 2d bFGF treated OHC more BrdU/DCX+ cells compared to control were observed in the 
CA1 or CA3 areas suggesting that bFGF could stimulate the migration of newly generated 
DCX+ cells from the pPV in the pyramidal layer. This effect was abolished by long bFGF 
application.  These  results  suggest  that  the  duration  of  GF  therapy  could  be  one  of  the 
parameters, which influence the neurogenic effect of exogenous GFs.
Taking together, two neurogenic zones in OHC: the DG and the pPV were described here. 
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Low basal neurogenesis was observed in the DG vs higher basal neurogenesis in the pPV. 
Neurons appearing in the SGZ of the DG assumed a granular cell morphology and could be 
found in the GCL of the DG. Neurons from the pPV stayed isolated from each other and were 
present in the pPV or distributed along the “stratum oriens-GE” and “DG-GE” borders. The 
precursor cells in the two neurogenic zones showed morphological and functional differences. 
bFGF  treatment  induced  a  fast  and  short-timed  neurogenesis  in  the  DG  while  the  pPV 
precursors showed a stronger and long lasting neurogenic response to bFGF stimulation. 
3.3. Cell damage, microglia activation and cell proliferation after OGD
12-14 DIV OHC were exposed to 40 min OGD (see Fig. 2.3). Cell damage, microglia 
activation,  and  cell  proliferation  was  detected  by  PI  uptake,  OX-42,  and  BrdU 
immunoreactivity respectively at different time points after OGD.
 
3.3.1. Cell damage after OGD
A gradual increase in necrotic cell death was observed from 0 to 24h after insult (Fig. 
3.10). 
Fig. 3.10. Cell damage occurring in OHC after OGD. OHC were exposed to 40 min OGD. Cell damage was 
evaluated by PI uptake at 0, 2, 6, 16 and 24h after insult. Transmission light images show OHC under control 
and OGD conditions. Fluorescent light images show PI uptake at different time points after OGD.
 
At 24h after insult pyramidal layer and GCL were strongly PI+. In the CA1 pyramidal 
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layer significant neuronal damage was observed at  6h (Fig.  3.11A) whereas in the DG it 
occurred at 16h after OGD (Fig. 3.11B). 
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Fig. 3.11. Quantification of cell damage in OHC after OGD. Integral density of PI uptake in the DG (A) and 
CA1 was quantified using Lucia Software. (C) Temporal profile of damage in pyramidal cell layer in control and 
OGD-treated OHC maintained for 15d after beginning of experiment. The data are expressed as the mean±SD, 
***P<0.001 (ANOVA followed by post-hoc Newman-Keuls  test).  (D) NeuN staining of  OHC maintained in 
culture for 15d (29DIV) after beginning the experiment. Scale bar 200 µM.
OHC maintained under control conditions for more than 5d (17-19DIV) after beginning 
of  experiment  (Fig.  3.11C)  did  not  show  the  increase  of  neuronal  degeneration  in  the 
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pyramidal cell layer. Later on, at 10d (22-24DIV) significant increase of PI uptake in the 
CA1-CA3 layers with further increase at 15d was defined. Due to the death and elimination of 
injured cell, cell damage in the pyramidal layer was decreased at 5d after OGD compared to 
1d (Fig. 3.11C). Low PI incorporation was observed also at 10d and 15d after OGD. NeuN 
staining of OHC maintained for 15d (29DIV) after OGD showed almost complete neuronal 
degeneration  of  the  slice  (Fig.  3.11D, right  panel)  whereas  under  control  conditions  (left 
panel) pyramidal and granular neuronal layers could be seen.
3.3.2. Activation of microglia after OGD
The majority of resident microglia in OHC in the absence of injury was found on the 
surface of the slice where, in addition to astrocytes, it formed the GE ensheathing the slice 
culture (see Fig. 3.1).
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Fig. 3.12. Temporal profile of microglia accumulation in theDG and CA1 after OGD. The data are expressed 
as the mean±SD, ***P<0.001 (ANOVA followed by post-hoc Newman-Keuls test).
At the same time, inside of the slice, low numbers of OX-42+ microglia were observed (Fig. 
3.12). A significant increase in microglia was found in the CA1 area at 2h after OGD with a 
further increase at 6h (Fig. 3.12B). The increase of microglia in the DG was gradual and 
reached significance at 16h (Fig. 3.12A). OX-42 immunostaining showed the morphological 
changes of microglia in OHC from ramified cells seen under control conditions (Fig. 3.13A) 
to amoeboid activated microglia after OGD (Fig. 3.13B). 
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Fig. 3.13. Change of morphology of microglia after OGD. OX-42 immunolabelling shows ramified microglia 
present in the CA1 under control conditions and activated amoeboid microglia after OGD. Scale bar 50 µm. 
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Fig. 3.14. Upregulation of pro-inflammatory cytokines after OGD. mRNA level of pro-inflammatory cytokines 
TNF-α, IL-1ß and IL-6 was assessed at 2, 4 and 8h after OGD. The data are expressed as the mean±SD, * P<0.05, 
** P <0.01 and ***P<0.001 (ANOVA followed by post-hoc Newman-Keuls test).
At 2h after OGD, early microglia activation was accompanied by an upregulation of 
pro-inflammatory cytokines mRNA level (Fig. 3.14). An increase of TNF-α (4x), IL-1ß (7x) 
and  IL-6  (4x)  mRNA  was  detected.  Increased  mRNA  level  of  these  pro-inflammatory 
cytokines was observed also at 4 and 8h after OGD.
3.3.3. Cell proliferation after OGD
A high cell proliferation was always found in the GE (see Fig. 3.2A). A low number of 
BrdU+  proliferating  cells  was  seen  after  40  min  of  BrdU  treatment  (OGD  period)  in 
cryosectioned OHC under control conditions (Fig. 3.15A, B).
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Fig. 3.15. Increase of cell proliferation in OHC after OGD. Quantification of BrdU+ cells in the CA1 (A) and 
DG (B) at early face (0-24h) after OGD. (C) BrdU immunolabelling shows the distribution of BrdU+ cells in OHC 
under control conditions (left panel) and the increase of cell proliferation 24h after OGD (right panel) compared to 
control. Scale bar 200 µm. (D) Quantitative comparison of cell proliferation in OHC at 1d, 3d and 6d after OGD. 
“*” represents the significant differences in number of BrdU+ cells between control and OGD in one area, “#” 
represents the significant differences in number of BrdU+ cells between 1d and 3d or 3d and 6d in one area. The 
data are expressed as the mean±SD, *P<0.05,  **,##P<0.01 and ***,###P<0.001 (ANOVA followed by post-hoc 
Newman-Keuls test).
Longer incubation with BrdU (for 24h) did not result in an increase of proliferating cells, 
neither in the CA1 area nor in the DG. After OGD, a significant increase of BrdU+ cells 
compared to control was revealed at 16h in the CA1 area (Fig. 3.15B) and at 24h in the DG 
(Fig. 3.15A). Massive increase of cell proliferation at 24h after OGD (Fig. 3.15C, right panel) 
compared  to  control  (Fig.  3.15C,  left  panel)  could  be  seen  in  the  whole  hippocampal 
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formation. At later time points after OGD (3d, 6d; 2d of BrdU application) further increase of 
BrdU+ cells was found (Fig. 3.15D). Moreover the number of proliferating cells increased 
significantly from 1d to 3d and from 3d to 6d of incubation after OGD.
3.3.4. Effect of growth factors on cell proliferation after OGD
To investigate the effect of exogenous GFs on cell proliferation under OGD conditions 
we treated OHC with BDNF 25 ng/ml, bFGF 5 ng/ml, EGF 10 ng/ml or NGF 10 ng/ml using 
the standard protocol (see Fig. 2.4). A decrease in BrdU+ cells compared to OGD was found 
in the DG and CA1 after short or long BDNF treatment (Fig. 3.16). 
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Fig. 3.16. Quantitative analysis of cell proliferation in OHC treated with exogenous GF after OGD. OHC 
were incubated with BrdU for 2d after OGD and were treated for 2d or 5d with one of the following GF in a final 
concentration of BDNF 25 ng/ml, bFGF 5 ng/ml, EGF 10 ng/ml or NGF 10 ng/ml. GF was added in culture 
medium at 24h after OGD and BrdU+ cells were detected at 3d and 6d after OGD. “*” represents the significant 
differences in number of BrdU+ cells between 3d and 6d GF treatment, “#” represents the significant differences in 
number of BrdU+ cells between OGD and OGD+GF treatment at the same time point. The data are expressed as 
the mean±SD, *P<0.05, **,##P<0.01 and ###P<0.001 (ANOVA followed by post-hoc Newman-Keuls test).
Long EGF or NGF application reduced cell proliferation in the both areas. In the cases of 
bFGF and EGF significant decrease of BrdU+ cells was observed in long treated cultures 
compared to short GF application. After having established the course of events after OGD 
and effect of GFs on OGD-regulated cell proliferation we were interested in the effect of 
injury on neurogenesis.
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3.4. Neurogenesis in OHC after OGD
To label proliferating cells, OHC were treated with BrdU for 2d after OGD. Early (3d) 
and  later  (6d)  neurogenesis  was  investigated  by  BrdU/DCX  and  BrdU/ß-III  Tubulin 
immunohistochemistry  (see  Fig.  2.4).  ß-III  Tubulin  immunostaining  showed  the  neuronal 
network of  OHC under  control  conditions (Fig.  3.17A) and the cyto-architecture of  CA1 
pyramidal layer (Fig. 3.17B).
Fig. 3.17. Neuronal structure of OHC and newly generated neurons after OGD. BrdU/DCX+ neuron in the 
pPV-stratum oriens area. ß-III Tubulin staining shows neuronal architecture of OHC under control conditions 
(A) and after OGD (C). The regions in the box in A and C are shown at a higher magnification in B and D 
respectively, demonstrating morphology of pyramidal CA1 neurons under control conditions and after OGD. (E) 
BrdU/ß-III  Tubulin+  neurons  with  neuroblast  morphology  in  the  molecular  layer  of  OHC after  OGD.  (F) 
BrdU/ß-III Tubulin+ neuron in the pyramidal CA3 layer of OHC after OGD. (G) BrdU/ß-III Tubulin+ neurons 
in the CA1 layer of OHC after OGD seem to assume the morphology of pyramidal cells. Scale bar: 500µm for A 
and C; 20µm for G; 10 µm for B, D, E and F.
After OGD the neuronal network was destroyed (Fig. 3.17C) since pyramidal CA1 neurons 
had degenerated and showed atrophy of dendritic processes as well as shrinkage of cell bodies 
(Fig. 3.17D). However, newly generated neurons were observed in OGD-exposed cultures 
(Fig. 3.17E, F). They were found in the molecular layer, the pyramidal cell layer, the pPV, 
stratum oriens and DG. The majority of newly generated neurons at 6d after OGD displayed 
neuroblast morphology. BrdU/ß-III Tubulin neurons with pyramidal cell morphology were 
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rarely found in the CA1 area of OGD exposed OHC (Fig. 3.17G).
Quantification  of  BrdU/DCX  and  BrdU/ß-III  Tubulin+  cells  showed  low  basal 
neurogenesis in the DG compared to the pPV (Fig. 3.18). Early after OGD (3d) a decrease of 
BrdU/DCX+ neurons was defined in both neurogenic zones. 
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Fig. 3.18. Neurogenesis in OHC after OGD. Quantitative analysis of neurogenesis in OHC under control and 
OGD conditions at 3d and 6d after OGD. The data are expressed as the mean±SD, *P<0.05; ***P<0.001 
(ANOVA followed by post-hoc Newman-Keuls test). 
Moreover  the  downregulation  of  DCX expression  was  seen  in  the  DG of  OGD exposed 
cultures (data not shown). However at a later time point (6d) restoration of neurogenesis was 
detected and a significant increase in the number of BrdU/DCX+ or BrdU/ß-III Tubulin+ cells 
was found in the pPV (Fig. 3.18).
3.4.1. bFGF increases neurogenesis in the pPV after OGD
To investigate whether the application of exogenous GFs can boost neurogenesis after insult 
in our system, we treated OHC with bFGF 5ng/ml for 5d (protocol see Fig. 2.4). At 6d after 
OGD we observed significant increase in number of BrdU/ß-III Tubulin+ neurons in the 
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pPV of  OGD-treated  OHC compared  to  control  (Fig.  3.19).  bFGF applied  after  OGD 
showed considerable neurogenic effect in the pPV, stimulating thus the tissue regeneration 
after neuronal loss.
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Fig. 3.19. Increase of neurogenesis by bFGF treatment after OGD. OHC were incubated with BrdU for 2d after 
OGD and treated for 5d with bFGF in a final concentration of 5 ng/ml. bFGF was added into the culture medium at 
24h after OGD and BrdU/ß-III Tubulin+ neurons were detected at 6d after OGD in the DG and pPV. The data are 
expressed as the mean±SD, *P<0.05, **P<0.01 (ANOVA followed by post-hoc Newman-Keuls test).
Taken together, these data showed the temporal relationship between neuronal damage, 
microglia  activation,  inflammation,  cell  proliferation  and  neurogenesis  (Fig.  3.20).  The 
inflammatory  reaction  was  already  evident  2h  after  insult.  At  the  same  time  point 
accumulation of microglia occurred in the CA1 area and reached the maximal level at 6h 
accompanied by significant neuronal damage. At 16h we found a considerable increase of cell 
proliferation. In the DG these effects were detected later compared to the pPV. Neurogenesis 
in OHC was detected in the DG and the pPV.
64
Fig. 3.20. Temporal interplay between microglia activation, inflammation, cell damage, cell proliferation and 
neurogenesis in OHC after OGD
Neurogenesis in the pPV was significantly higher than the one in the DG. At 3d after insult, 
neurogenesis was inhibited but the increase of neurogenesis was already observed at 6d. At 
this time point neurogenesis was significantly increased in the pPV, while attenuation of cell 
damage has been found.  Continual  increase in  cell  proliferation took place and could be 
downregulated  by  exogenous  GFs  treatment.  We  further  assessed  the  contribution  of 
inflammation in OGD-induced changes and neurogenesis by blocking the inflammation with 
anti-inflammatory compounds.
3.5. Anti-inflammatory treatment
To investigate the contribution of inflammation to the complex sequence of pathological 
events  and  neurogenesis,  OHC  were  treated  with  anti-inflammatory  compounds:  the 
nonselective COX inhibitor indomethacin or the inhibitor of p38 MAPK minocycline at a 
final  concentration of 10 or 50 µM. A MK-801 (10µM) treated group was included as a 
positive control for neuroprotection. Compounds were added for 2h before, during and until 
2d after OGD (see Fig. 2.5). Cell damage and the number of OX-42+ microglia were detected 
24h after insult. Cell proliferation and neurogenesis was assessed at 6d after OGD with the 
early neuronal marker DCX.
3.5.1. Anti-inflammatory treatment reduces neuronal damage after OGD
Neither indomethacin nor minocycline induced neuronal damage in OHC under control 
conditions  (Fig.  3.21).  MK-801,  indomethacin  or  minocycline  treatment  significantly 
prevented OGD-induced neuronal injury. The effect of indomethacin or minocycline was less 
pronounced compared to MK-801. 
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Fig. 3.21. Effect of anti-inflammatory treatment on cell damage after OGD. 12-14DIV OHC were treated 
with indomethacin (10 or 50µM) or minocycline (10 or 50µM) for 2h before, during and 2d after OGD. MK-801 
(10µM) was used as a positive control of neuroprotection. At 24h after OGD, cell damage was assessed by PI 
uptake.  The  data  are  expressed  as  the  mean±SD,  **P<0.01;  ***P<0.001  (ANOVA  followed  by  post-hoc 
Newman-Keuls test). IN, indomethacin; MI, minocycline; MK, MK-801; Veh, 0.1% ethanol. 
3.5.2. Anti-inflammatory treatment reduces the numbers of microglia after OGD 
A decreased number of microglia in the DG of OGD-exposed cultures treated with MK-
801, indomethacin or minocycline was observed (Fig.  3.22).  A significant reduction of 
microglia was also defined in the CA1 area after treatment with MK-801, indomethacin (10 
µM) and minocyclin (50 µM). Treatment with indomethacin (50 µM) resulted in a slight 
decrease of microglia in the CA1 area (P=0.106, vs OGD) whereas minocycline (10 µM) 
did not display this effect.
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Fig. 3.22. Effect of anti-inflammatory treatment on microglia after OGD. 12-14DIV OHC were treated with 
indomethacin (10 or 50µM) or minocycline (10 or 50µM) for 2h before, during and 2d after OGD. MK-801 
(10µM) was used as a positive control of neuroprotection. At 24h after OGD, microglia was assessed by OX-42 
immunostaining. The data are expressed as the mean±SD, *P<0.05; **P<0.01; ***P<0.001 (ANOVA followed 
by post-hoc Newman-Keuls test). IN, indomethacin; MI, minocycline; MK, MK-801; Veh, 0.1% ethanol.
3.5.3. Anti-inflammatory treatment reduces cell proliferation after OGD 
We also observed that MK-801, indomethacin or minocycline abolished OGD-induced 
cell proliferation in the DG and CA1 (Fig. 3.23). This effect has been seen at 6d after OGD 
when the high level of proliferation was found.
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Fig. 3.23. Effect of anti-inflammatory treatment on cell proliferation after OGD. 12-14DIV OHC were 
treated with indomethacin (10 or 50µM) or minocycline (10 or 50µM) or MK-801 (10µM) for 2h before, during 
and 2d after OGD. Proliferating cells were labeled by BrdU for 2d after OGD. BrdU+ and BrdU/DCX+ cells 
were  detected  at  6d.  The  data  are  expressed  as  the  mean±SD,  *P<0.05;  **P<0.01;  ***P<0.001 (ANOVA 
followed by  post-hoc  Newman-Keuls  test).  IN:  indomethacin;  MI:  minocycline;  MK,  MK-801;  Veh,  0.1% 
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ethanol.
3.5.4. Anti-inflammatory treatment and neurogenesis after OGD
3.5.4.1. MK-801 treatment and neurogenesis
MK-801 at a final concentration of 10 µM increased (P=0.045, MK-801 vs control) 
neurogenesis  in  the  pPV under  control  conditions  (Fig.  3.24).  A  reduction  in  BrdU/ß-III 
Tubulin+  cells  was  observed  in  OGD-exposed  cultures  treated  with  MK-801.  DG 
neurogenesis was not affected by MK-801 treatment.
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Fig. 3.24. Effect of MK-801 treatment on neurogenesis after OGD. OHC were treated for 2h before, during 
and 2d after OGD with MK-801 in final concentration of 10µM. Cultures were incubated with BrdU for 2d after 
OGD and newly generated neurons were detected at 6d with BrdU/DCX immnunolabeling. Influence of MK-
801 treatment on basal and OGD-induced neurogenesis.  The data are expressed as the mean±SD, *P<0.05; 
**P<0.01; ***P<0.001 (ANOVA followed by post-hoc Newman-Keuls test). MK, MK-801.
3.5.4.2. Anti-inflammatory treatment and neurogenesis
Indomethacin (Fig. 3.25A) or minocycline (Fig. 3.25B) showed neurogenic properties, 
increasing the number of BrdU/DCX+ cells in the pPV under control conditions (P<0.001, 
indomethacin  10µM  vs  control;  P=0.048,  indomethacin  50µM  vs  control;  P=0.009, 
minocycline 10µM vs control).  A higher  concentration of  minocycline  did not  show this 
effect (P=0.653, minocycline 50 µM vs control). Neurogenesis in the pPV was significantly 
increased at 6d after OGD compared to control (P<0.001, OGD vs control). 
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Fig. 3.25. Effect of anti-inflammatory treatment on neurogenesis after OGD. OHC were treated for 2h 
before, during and 2d after OGD with indomethacin (A) or minocycline (B) in a final concentration of 10µM or 
50 µM. Cultures were incubated with BrdU for 2d after OGD and newly generated neurons were detected at 6d 
with BrdU/DCX immnunolabeling.  The data are expressed as the mean±SD, *P<0.05; **P<0.01; ***P<0.001 
(ANOVA followed by post-hoc Newman-Keuls test). IN: indomethacin; MI: minocycline; Veh, 0.1% ethanol.
OGD-induced neurogenesis in the pPV whereas indomethacin (10 or 50 µM) or minocycline 
(10 µM) did not  affect  it.  However neurogenesis  was reduced after  OGD in the vehicle-
control group (0.1% ethanol) (P=0.106, vehicle vs OGD) or the group treated with a higher 
concentration of minocycline (P=0.058, minocycline 50µM vs OGD). In the DG no difference 
in the number of BrdU/DCX+ cells was detected between control and treated groups. 
Thus, our results demonstrated that blockade of NMDA receptors by MK-801 as well 
as  inhibition  of  COX by  indomethacin  or  p38  MAPK  by  minocycline  prevented  OGD-
induced neuronal  injury,  microglia  activation and migration.  That  in  turn reduced injury-
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induced cell proliferation. Indomethacin (10 or 50 µM) or minocycline (10 µM) displayed a 
neuroprotective effect, and did not interfere with OGD-induced neurogenesis. Whereas MK-
801 slightly decreased neurogenesis under OGD conditions.
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4. Discussion
In the first part of this study basal cell proliferation and neurogenesis in interface OHC 
was characterized. OHC were prepared from P7-9 rats and maintained in vitro for 14d before 
the proliferating cells were labeled with BrdU.
4.1. Glial envelope and proliferating cells in OHC
The initial trauma during preparation and subsequent cultivation stimulated astrocytes to 
proliferate  and form a glial  barrier  ensheathing the slice  (glial  envelope).  The presence  of 
activated astrocytes expressing Nestin and activated microglia indicated a protective function of 
the GE . We found massive cell proliferation in the GE (surface of the slice) compared to low 
proliferation  inside  the  slice.  However,  due  to  the  young  age  of  animals  used,  the  cell 
proliferation  inside  the  slice  was  higher  compared  to  the  proliferation  found  in  the  adult 
hippocampus in vivo . Roughly the same proliferation rate could be detected in DG, CA1 or 
CA3 areas. This has also been reported in roller-tube OHC . The cell proliferation significantly 
increased between 1d and 3d of incubation indicating the difference in the duration of BrdU 
presence. However the number of proliferating cells did not change over time during the further 
incubation period from 3d to 10d. Cell proliferation in OHC was affected by exogenous bFGF 
or  EGF  (Table  4.1).  While  EGF  could  increase  the  number  of  BrdU+  cells  after  short 
application (2d), longer incubation (5d) was needed to stimulate proliferation by bFGF. At the 
same time long EGF treatment resulted in significant reduction of BrdU+ cells after initial 
increase  whether  due  to  the  apoptosis  and  death  or  migration  of  newly  generated  cells. 
Exogenous BDNF or NGF did not interfere with basal cell proliferation in our system either due 
to the low binding affinity of GFs receptors or sufficient level of endogenous GFs in the tissue .
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4.2. Identification of a second neurogenic zone in OHC and morphological differences of 
DG and pPV precursors
In addition to the Nestin+ astrocytes and the small Nestin+ cells with stellar morphology 
in the GE, other morphologically different Nestin+ cell populations could be observed in OHC. 
The DG contained larger Nestin+ cells with stellar morphology while elongated Nestin+ cells 
were present in the “stratum oriens-GE border”. This structure could be the remainder of the 
secondary dentate matrix and dentate migration path. However in P7-9 rat hippocampus these 
structures are already diminished  and neurogenesis  in the secondary dentate  matrix is  not 
longer  present  during  the  cultivation  of  OHC .  Therefore  we  hypothesized  that  elongated 
Nestin+ cells might be derived from the pPV. The pPV is adjacent to the hippocampus as a part 
of the embryonic LV which contains precursor cells displaying in vitro stem cell properties . In 
the absence of injury stem cells in the adult brain pPV are  dormant and can  proliferate and 
migrate into the CA1 area in response to global ischemia following GF treatment . Elongated 
Nestin+ cells in the pPV were observed in sham operated and ischemic adult rats  (C. Pforte, 
unpublished observation). Here  we found that these cells generated DCX and  ß-III Tubulin+ 
neurons which formed the structure of the pPV between the cortex and the hippocampus in 
OCC. After  separating the hippocampi from the cortex during slice preparation a part of the 
pPV was also present in the OHC. Cross sections of OHC showed that the GFAP- and ß-III 
Tubulin-negative  tissue  above  the  dorsal  hippocampus  (“CA1-side”)  contained  elongated 
Nestin+  cells.  The  morphology  (elongated  Nestin+)  and  in  situ  appearance  (cell  clusters 
forming a dense network) of cells was similar to Nestin+ precursors of the pPV. Thus, in the 
OHC besides the DG we could identify the pPV as a second neurogenic zone. These zones are 
characterized by two morphologically different populations of precursors.
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4.3. Functional differences of DG and pPV precursors
4.3.1. Low neurogenesis in the DG compared to high neurogenesis in the pPV
We  revealed  also  functional  differences  between  two  precursor  populations.  Low 
neurogenesis  was observed in  the DG in contrast  to  higher  neurogenesis  in  the  pPV. The 
number of newly generated neurons in the pPV increased in number up to 10d after BrdU 
application and significantly exceeded the number of newly generated neurons in the DG. In the 
DG the amount of newborn neurons (basal neurogenesis) did not change during the whole 
experimental period (10d). It has been described that neurogenesis in the DG in roller-tube 
cultures is reduced in the presence of serum . In our system the presence of serum significantly 
decreased neurogenesis in the pPV while DG basal neurogenesis was not affected (data not 
shown).
4.3.2.  Punctuated  pattern  of  BrdU+  nuclei  of  newly  generated  neurons  in  the  DG 
compared to even stained neuronal nuclei in the pPV
Neuronal precursors in the pPV seemed to display the characteristics of quickly dividing 
cells. This could also explain the different pattern of BrdU immunolabeling in the nucleus of 
cells generated in the DG and pPV. The S phase of the cell cycle of pPV precursors is probably 
faster than that of precursors in the DG. Thus, 2d of BrdU incubation may be long enough to 
label a sufficient number of newly generated neurons. Since very rarely neurons in the pPV 
showed punctuated pattern of BrdU labeling, we suggest that these cells were generated after 
removing of BrdU from the culture medium. The long cell cycle of DG precursors maybe 
prevented abundant BrdU incorporation and thus caused the punctuated BrdU staining pattern 
in the nucleus in a majority of newly generated neurons in the DG.
In contrast Liu et al. observing the punctuate labeling of BrdU in many cells in the DG 
after global ischemia suggested the dilution of label by several cycles of cell division . In this 
case DG precursors in our system should have high proliferating rate since punctuated pattern 
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of BrdU labeling could be seen already in BrdU/DCX+ cells detected 3d after BrdU application. 
However basal DG neurogenesis in our juvenile interface OHC was lower compared to roller-
tube OHC and in vivo studies . The difference in the number of newly generated neurons in 
roller-tube cultures could be explained by differences in age (P7 vs P5), species (rat vs mice) of 
the animals, culture conditions and experimental setup (14d vs 17d), BrdU treatment protocol 
(2d vs 3d), thickness of analyzing slices (20µm vs 50-100µm) and neurogenic markers used 
(DCX, ß-III Tubulin vs NeuN). The permanent interface air-tissue system might influence the 
activity of DG precursors in differently compared to continuous alternation of feeding and 
aeration  in  the  roller-tube  cultures  .  Neurogenesis  in  the  DG  was  lower  compared  to 
neurogenesis in vivo. Evidently, the neuronal precursor cells in the DG are restricted in the 
potential while the glial precursors dominate under in vitro conditions. This may have occurred 
because  different  environmental  cues  present  in  the  DG  and  dentate  hilus  influence  the 
developmental fate of CNS progenitors.
4.3.3. Maturation of newly generated neurons in the DG and pPV
In the DG newly generated neurons could be observed at 3d after BrdU application. At 
10d they displayed a granular cell morphology, however only few of them expressed NeuN. In 
spite of the long incubation period (10d) the majority of BrdU/ß-III Tubulin+ neurons in pPV 
retained  a  neuroblast  morphology.  We  assumed  that  newly  generated  neurons could  not 
complete the maturation and died shortly after generation however the increase observed on 10d 
suggests that majority of cells survive. Hence, the maturation of newly generated neurons in the 
pPV seems to be slower compared to the DG and longer time may be required for the complete 
maturation. A comparable delay of glial development in organotypic slice cultures was reported 
by del Rio . Furthermore, for the neuronal differentiation of neuroblasts the migration to the 
olfactory bulb through the RMS from the SVZ or into the GCL from the SGZ is thought to be 
necessary . However in our system neuroblasts generated in the pPV did not formed migratory 
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stream, remaining in the pPV, migrating to the stratum oriens or along the slice border or into 
the CA3 and CA1 pyramidal layer. The morphological characteristics (shape of the cell body, 
size) of the majority of newly generated neurons in pPV indicated that they seemed to be 
interneurons. The use of markers specific for neuronal subpopulations as well as following the 
fate beyond 10d are both suitable approaches to elucidate the fate of newly generated neurons as 
well as their ability to integrate into the neuronal circuitry.
 
4.3.4. Effect of growth factors on neurogenesis in OHC
Neurogenesis in the DG and the pPV was stimulated by short (2d) bFGF treatment, however a 
significant increase was revealed only in the pPV (see Table 4.1). The bFGF-induced increase 
of neurogenesis  in the DG at  2d proved to be only temporary since the number of newly 
generated neurons in the DG decreased later on (5d treatment).  Either the newly generated 
neurons might not survive or they migrated from the DG to the pyramidal cell layer . In contrast 
to the DG, the bFGF effect on neurogenesis in the pPV pointed at more potent neurogenic and 
survival  properties  of  pPV  precursors.  Similar  to  the  effect  of  EGF  on  cell  proliferation 
extended  EGF  treatment  (5d)  reduced  neurogenesis  in  the  pPV  with  no  effect  on  DG 
neurogenesis. That could point either on induction of apoptosis and elimination of neuronal 
progenitors or stimulation of progenitors to differentiate in glial cell lineage by EGF treatment 
(Kuhn et al., 1997). Neither BDNF nor NGF could affect neurogenesis in our system. 
Table 4.1. Effect of exogenouse GFs on basal cell proliferation and neurogenesis in OHC
Parameter bFGF EGF BDNF NGF
2d 5d 2d 5d 2d 5d 2d 5d
Proliferation No
effect
Increase Increase 
(CA1)
Decrease No 
effect
No 
effect
No 
effect
No 
effect
Neurogenesis Increase Increase
(pPV)
n.d. Decrease
(pPV)
n.d. No 
effect
n.d. No 
effect
n.d., not determined
Here we described the neurogenesis in vitro in OHC. We showed for the first time that in 
75
addition to the DG with the pPV there is a second neurogenic zone present in OHC (Fig. 4.1). 
Stellar larger Nestin+ cells were found in the DG while elongated Nestin+ cells were observed 
in  the  pPV.  Precursors  from  the  DG  showed  a  fast  but  insignificant  response  to  bFGF 
stimulation. pPV precursors had a fast and efficient response to bFGF and seemed to possess 
more potent neurogenic properties. 
Fig. 4.1. Schematic drawing of the neurogenic zones present in OHC. Stars represent precursors in the DG; 
big black dots represent precursors in the pPV; small white dots represent newly generated neurons in the DG; 
small grey dots represent newly generated neurons in the pPV. 
EGF was able  to  reduce  pPV neurogenesis  without  affecting the  DG neuronal  precursors. 
Hence, the difference between the DG and pPV response to GFs could be explained by either a 
differential  regulation  of  these  two  neuronal  precursor  populations  by  GFs  or  different 
proliferation rate/turnover.  Since pPV precursors did not  express GFAP they could not  be 
characterized as SVZ stem cells but may be as subependymal cells reported by Seaberg and van 
der Kooy . These authors showed significant stem cell properties of subependymal cells isolated 
from the areas surrounding the hippocampus (posterior LV, 3rd ventricle and “hippocampal 
arch”). However, the in vitro assays of multipotenciality and self-renewal are much dependent 
form the experimental protocol used for isolation of precursor cells (Kempermann G., personal 
communication). Moreover the finding that ependimal cells do not incorporate mitotic markers 
at any of the survival times studied indicates that these cells are not the primary precursors of 
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the newborn neurons (Gage et al., 2004). Thus, we assumed that the elongated Nestin+ cells 
observed in the pPV could be the rapidly dividing transit-amplifying cells (type C) which are 
derived from the SVZ astrocytes (stem cells, type B) and lack the expression of GFAP but still 
able to divide.
4.4. Cell damage, microglia activation and cell proliferation after OGD
Based on the reported observation that neurogenesis in the DG and SVZ  is increased in 
response to neuronal damage we used OHC to investigate the complex interplay between 
neuronal damage, microglia activation, inflammation, cell proliferation and neurogenesis after 
OGD.
4.4.1. Microglia activation and neuronal damage preceded cell proliferation after OGD 
Resident  microglia  are  activated  rapidly  after  the  onset  of  ischemia  .  Microglia 
transform into  phagocytes  and  remove  necrotic  neurons  but  sparing  eventually  surviving 
neurons even in close vicinity of necrotic neurons . Here we described an increase in activated 
microglia in the CA1 area as early as 2h after the insult. Inflammation in OHC was mounted 
at  an  early  time  point  after  OGD  (2h)  and  associated  with  upregulation  of  the  pro-
inflammatory cytokines IL-1β, TNF-α and IL-6 mRNA level. At 6h after OGD a significant 
loss of CA1 pyramidal neurons simultaneously with a massive increase of microglia in the 
CA1 area was identified. At a later time point neuronal injury and microglia activation were 
revealed in the DG confirming a higher vulnerability of CA1 pyramidal neurons to OGD 
compared to DG granular neurons. Since a significant increase in BrdU+ cells in the CA1 was 
found at 16h after OGD, the fast increase of microglia seen (2-6h after OGD) was clearly due 
to cell migration and not proliferation. The microglia are probably derived from the GE where 
activated microglia were present even under control conditions . Accumulation of microglia in 
the damaged area could suggest a detrimental (inflammation and secondary damage) as well 
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as a beneficial (neuronal support) role of this cell population in the CNS tissue after injury .
4.4.2. MK-801, indomethacin or minocycline treatment showed a neuroprotective effect
We demonstrated that treatment with indomethacin or minocycline resulted in a marked 
neuroprotective effect against OGD-induced injury in OHC. Administration of indomethacin 
after  OGD in OHC was first  reported by Arai et  al.  .  They, however,  could not detect a 
neuroprotective effect of indomethacin, maybe due to a shorter duration of treatment (from 40 
min before until  40 min after  the OGD).  In  our  study indomethacin or  minocycline also 
reduced the number of microglia in the CA1 and DG after OGD. The neuroprotective effect 
of indomethacin is likely to result from COX-2 inhibition in turn inhibiting PGs production. 
Involvement of the other effects of indomethacin, such as direct scavenging of NO radicals or 
activation  of  peroxisome  proliferator-activated  receptors,  could  also  contribute  to 
neuroprotection . Minocycline inhibits the p38 MAPK pathway, which is implicated in signal 
transduction leading to iNOS expression in glial cells and apoptosis of neurons . Reduction of 
COX-2  expression,  prostaglandin  synthesis  and  inhibition  of  the  induction  of  IL-1ß-
converting enzyme by minocycline  was also  reported .  There  is  evidence that  COX-2 is 
upregulated  in  late  stages  of  injury  and  COX-2  reaction  products  contribute  to  NMDA-
mediated  cytotoxicity   whereas  NMDA-receptors  are  directly  involved  in  OGD-induced 
neuronal  injury  . Therefore  blockage  of  NMDA  receptors  by  MK-801  showed  a  more 
prominent neuroprotective effect compared to indomethacin or minocycline. Evidence that 
MK-801  strongly  reduces  cytokine  expression  ,  especially  TNF-α  either  by  preventing 
neuronal damage or direct effect on TNF-α production, also contribute to neuroprotective 
activity of this NMDA-receptor antagonist.
4.4.3. Cell proliferation and cell damaged at later time points after OGD 
Phagocytosis of injured cells by activated microglia results in the removal of apoptotic 
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cells and cell debris from damaged tissue and subsequent stimulation of tissue reconstruction . 
GFs like bFGF, BDNF, erythropoietin and hypoxia induced factor have been described to be 
released from activated microglia  and astrocytes  after  injury .  They upregulate  cell  cycle 
proteins,  which  in  turn  control  cell  proliferation,  differentiation  and  survival.  Microglia 
proliferate earlier than astrocytes in response to cerebral ischemia . At 16h after OGD we 
found a significant increase of BrdU+ cells in the CA1 area (24h in the DG). Neuroprotection 
with MK-801,  indomethacin or  minocycline  reduced the increased microglia  proliferation 
seen after OGD. Continued increase of cell proliferation from 1d to 6d after the insult has 
been seen. In contrast cell damage decreased gradually from 1d to 5-6d after OGD probably 
due to the removal of injured neurons by activated microglia. Low cell damage has been also 
seen at 10d and 15d after OGD. At that time point neuronal structure of OGD-exposed OHC 
was completely destroyed compared to control cultures and massive astrogliosis as well as 
present of activated microglia took place.
 
4.4.4. Effect of exogenous growth factors on cell proliferation after OGD 
Increase of cell proliferation after OGD was abolished by exogenous GFs treatment (see 
Table 4.2). Short BDNF application as well as long BDNF, NGF or EGF treatment reduced 
the number  of  BrdU+ cells  seen after  OGD. Since  the neuronal  degeneration in  OHC is 
associated with high proliferative activity, reduction of cell proliferation could indicate earlier 
reported neuroprotective properties of GFs . Neuroprotective effect of BDNF could arise via 
its  ability  to  block  the  mechanism by  which  pathophysiologycal  Ca2+ influx  through  the 
NMDA receptor causes membrane PKC inactivation, seen after cerebral ischemia .
Table 4.2. Effect of exogenous GFs on cell proliferation in OHC after OGD
bFGF EGF BDNF NGF
2d 5d 2d 5d 2d 5d 2d 5d
No effect No effect
Decrease*
No effect Decrease
Decrease*
Decrease Decrease No effect Decrease
(DG)
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∗Compared to 2d treatment.
4.5. Neurogenesis in OHC after OGD 
At 3d after OGD, neurogenesis in both neurogenic zones (DG and pPV) was inhibited 
either due to the disturbance of the neurogenic microenvironment by inflammation/neuronal 
degeneration, to a direct effect of activated microglia on progenitor cells , or due to massive 
glutamate  release  .  We observed  that  in  the  DG of  OGD-exposed  slices  microglial  cells 
formed clusters localized directly in the SGZ. Numerous activated microglia were also present 
in the pPV. In accordance to previous studies  the IL-6 upregulation detected after OGD could 
be  responsible  for  the  inhibition  of  neurogenesis  ovserved  early  after  injury  .  The 
inflammatory microenvironment could support the dominant proliferation of glial rather than 
neuronal precursors thus reducing neurogenesis .
After neuronal degeneration had peaked, mechanisms of tissue reparation could take 
place.  The  attenuation  of  the  inflammatory  reaction  as  well  as  the  loss  of  glutamatergic 
neurons could promote neurogenesis . At 6d after OGD, restoration of neurogenesis in both 
neurogenic zones was detected. Moreover in the pPV, but not in the DG, neurogenesis after 
OGD was significantly increased supporting the hypothesis of functional differences between 
the DG and pPV precursors .  Since we studied neurogenesis  early  after  injury using the 
cellular markers of immature neurons we excluded that BrdU might label cells postmitotic 
neurons, which can reenter the cell cycle as a prelude to apoptosis after brain injury . 
Increase of newly generated BrdU/β-III Tubulin+ neurons could be also observed at 10d 
after OGD (data not shown). However, at  that time point the majority of injured neurons 
underwent  to  degeneration  (β-III  Tubulin+  staining)  and  post-ischemic  increase  of 
neurogenesis fails to provide the regeneration of lost tissue demonstrating limited capacity of 
endogenous repair mechanisms. In our system bFGF applied for 5d after OGD was able to 
stimulate neurogenesis in the pPV as detected 6d after the insult. A beneficial effect of GFs 
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was  recently  showed  by  Nakatomi  et  al.  where  combination  of  bFGF and  EGF infused 
bilaterally  into  the  ventricle  of  ischemic  rats  stimulated  morphological  and  functional 
recovery of CA1 pyramidal neurons . Thus, GF therapy can represent a promising approach 
for regeneration of neuronal loss.
4.6. Neuroprotection and neurogenesis 
4.6.1. MK-801 increased basal and reduced OGD-induced neurogenesis in the pPV
Neurogenesis  in  the  developing  and adult  brain  is  negatively  regulated,  in  part,  by 
NMDA receptors having a negative impact . We observed an increase of basal neurogenesis 
in  the  pPV  after  MK-801  treatment.  Stimulation  of  neurogenesis  by  NMDA  receptor 
antagonists  has  also  been  shown  in  vivo .  The  neuroprotective  effect  of  MK-801  was 
associated with a reduction in OGD-induced neurogenesis in the pPV indicating probably the 
survival of glutamatergic neurons, which have the projection to progenitor cells.
4.6.2. Indomethacin or minocycline increased basal neurogenesis and did not interfere 
with OGD-induced neurogenesis in the pPV
Indomethacin (10 or 50 µM) or minocycline (10 µM) stimulated basal neurogenesis in 
the  pPV  but  not  in  the  DG.  The  induction  of  basal  neurogenesis  by  anti-inflammatory 
compounds could be explained by an ongoing latent pro-inflammatory state of OHC even 
under  control  conditions  thus  causing  some  depression  of  neurogenesis.  However  a 
neurogenic effect of anti-inflammatory compounds was also not found in the DG in vivo . 
Although indomethacin (10, 50µM) or minocycline (10µM) reduced neuronal damage 
after OGD, they did not interfere with OGD-induced neurogenesis. Similar to our data Kluska 
et al. demonstrated the increase of hippocampal neurogenesis in the adult rats treated 30 min 
prior and 16d after phototrombotic insult  .  In contrast,  Sasaki with co-authors showed an 
inhibition of ischemia-induced proliferation of progenitors by indomethacin application after 
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global ischemia. However, the further fate of these progenitors was not clarified . Moreover in 
this in vivo study indomethacin was injected at the proliferation peak of DG progenitors (on 8-
9d after ischemia),  when the neuronal damage had already developed and mechanisms of 
neurogenesis were activated. This was clearly different from our experimental design (pre- 
and post- insult treatment). We observed an inhibition of neurogenesis after OGD only with a 
high concentration of minocycline (50µM). One possible hypothesis is that a certain degree of 
inflammation is  needed for  injury-induced neurogenesis.  However,  at  this  stage definitive 
conclusions regarding the role of microglia in this process cannot be drawn since the anti-
inflammatory compounds (indomethacin or minocycline) do not provide selective microglia 
inhibition, but can also affect neurons and astrocytes.
Since previous studies on the role of inflammation and neurogenesis using different 
experimental setups  have not shown a consistent uniform picture, one has to consider that the 
role of inflammation might depend on the type and degree of injury as well as the time point 
of interference.
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Fig. 4.2.  Mechanism of involvement of inflammation in neuronal damage and neurogenesis in OHC 
after OGD. 
4.7. Conclusion
Neuronal precursors with different neurogenic properties which were described in vivo are 
present in OHC. Morphological and functional differences of these cells could reflect their 
different  role  in  the  regeneration  after  neuronal  loss.  The  sequence  of  events  in  the 
(patho)physiological response after OGD provide evidence that inflammatory reaction is 
involved in OGD-induced neuronal damage (Fig. 4.2). The inflammation occurred early 
after  insult  is  associated  with  production  of  pro-inflammatory  cytokines  by  activated 
microglia, astrocytes and injured neurons as well as production of iNOS and activation of 
COX-2. The level of neuronal degeneration seems to determinate the cytotoxic potential of 
microglia  .  We could  confirm the  previously described  neuroprotective  effects  of  anti-
inflammatory compounds  against OGD-induced neuronal damage in OHC.  However we 
cannot conclude that microglia are the main culprits of neuronal degeneration since anti-
inflammatory  compounds  (indomethacin  or  minocycline)  could  not  provide  selective 
microglia  inhibition  but  can  affect  also  neurons  and  astrocytes.  Activated  microglia 
eliminate debris of death cells and together with astrocytes uptake the glutamate released in 
response to injury. Neurotrophic factors released from activated microglia and astrocytes 
rescuer the damaged cell and sustain their survival. At early face of insult the inflammatory 
reaction contributes to the change of neurogenic microenvironment that does not support the 
proliferation of neuronal precursors. However neurogenesis as a compensatory mechanism 
of neuronal loss is activated later, after the pick of degeneration went down.  We suggest 
that depending on the time point inflammation probably has both negative and positive 
effects  on neurogenesis.  Moreover,  this  in vitro study shows that an anti-inflammatory 
approach being neuroprotective seems not to interfere with insult-induced neurogenesis as a 
potential repair mechanism.
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6. Abbreviations
AMPA 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propionate
BDNF brain-derived neurotrophic factor
bFGF basic fibroblast growth factor
BrdU bromodeoxyuridine
CA cornu ammonis
CNS central nervous system
COX cyclooxygenase
d day
DCX doublecortin
DG dentate gyrus
DIV days in vitro
DNS donkey normal serum
EGF epidermal growth factor
FGF fibroblast growth factor
GCL granular cell layer
GE glial envelope
GF/GFs growth factor/growth factors
GFAP glial fibrillary acidic protein
IB4 Griffonia simplicifolia Isolectin B4
IL interleukin
IN indomethacin
LV lateral ventricle
LVw lateral ventricle wall
MAP-2 microtubule assotiated protein
MAPK mitogen activated protein kinase
MCAO middle cerebral artery occlusion
MI minocycline
MK MK-801
ML molecular layer
NeuN neuronal niclei
NGF nerve growth factor
NMDA N-methyl-D-aspartate
NO nitric oxide
NOS nitric oxide synthase 
OB olfactory bulb
OCC cortex-hippocampal organotypic slice cultures
OGD oxygen-glucose deprivation
OHC organotypic hippocampal slice cultures
P postnatal day
PBS phosphate buffered saline
PCNA proliferating cell nuclear antigen
PFA paraformaldehyde
PGs prostaglandins
PI propidium iodide
PKC protein kinase C
pPV posterior periventricle
RMS rostral migratory streem
RT room temperature
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SCF stem cells factor
SGZ subgranular zone
SVZ subventricular zone
TBS tris buffered saline
TNF tumor necrosis factor
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Appendices
I. ZUSAMMENFASSUNG 
Adulte  neurogenese  spielt  eine  Rolle  bei  vielen  physiologischen  (z.B. 
Gedächtnisbildung) und pathologischen (z.B. Schlaganfall, Depression) Prozessen. In neueren 
Studien  wurde  eine  erhöhte  Neurogenese  als  Antwort  auf  eine  Verletzung  des  Gehirns 
gezeigt,  die  als  ein  Mechanismus  der  Regeneration  nach  dem  Verlust  von  Neuronen 
angesehen wird. Es gibt Hinweise darauf, dass eine Vielzahl von Faktoren, wie z.B. Glutamat, 
Entzündungs- und Wachstumsfaktoren, zum Anstieg der Proliferation und Differenzierung 
von  Vorläuferzellen  nach  einem  Insult  beitragen.  Der  Mechanismus,  der  durch  eine 
Verletzung Neurogenese induziert, ist bisher jedoch weitgehend unklar.
In der vorliegenden Studie wurde die frühe Neurogenese in vitro an organotypischen 
Hippokampusschnittkulturen  der  Ratte  (OHC)  charakterisiert  und  das  komplizierte 
Wechselspiel  zwischen  neuronaler  Schädigung,  Mikroglia-Aktivierung,  Zellproliferation, 
Neurogenese  und  der  Rolle  der  Entzündung  nach  Sauerstoff-Glukose  Entzug  (OGD) 
untersucht. Außerdem wurde die Wirkung exogener Wachstumsfaktoren, nämlich des basalen 
Fibroblastenwachstumfaktors  (bFGF),  des  epidermalen  Wachstumfaktors  (EGF),  des  vom 
Gehirn  gebildeten  neurotrophen  Faktors  und  des  Nervenwachstumfaktors,  auf  die 
Proliferation  und  die  Neurogenese  in  OHC  bei  Anwesenheit  und  Abwesenheit  einer 
Schädigung überprüft. 
Die  Proliferation  wurde  über  die  Aufnahme  von  Bromodeoxyuridin  (BrdU),  die 
Neurogenese durch eine Doppelmarkierung mit Bromodeoxyuridin und Doublecortin (DCX) 
oder  ß-III Tubulin, die neuronale Schädigung über die Propidiumiodidaufnahme, Mikroglia 
durch eine OX-42 Färbung und proentzündliche Zytokine mittels Echtzeit-RT-PCR bestimmt. 
Es  wurde  eine  massive  Zellproliferation  in  der  glialen  Umhüllung  des  Schnittes 
beobachtet. Die gliale Umhüllung wurde während der Kultivierung der Schnitte von GFAP 
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bzw.  GFAP/Nestin-positiven  Astrozyten  sowie  aktivierter  Mikroglia  gebildet.  Die 
Proliferation  innerhalb  der  Schnittkultur  war  geringer.  bFGF und  EGF  zeigten  mitogene 
Eigenschaften und erhöhten die Zahl BrdU-positiver Zellen. Es konnte gezeigt werden, daß es 
in  OHC  zusätzlich  zum  Gyrus  dentatus  (DG)  eine  weitere  neurogene  Zone  gibt:  den 
posterioren Periventrikel (pPV), der einen Teil der lateralen Ventrikelwand darstellt. Diese an 
das Stratum oriens grenzende Struktur enthielt Nestin-positive Vorläuferzellen. Es konnten 
morphologische  und  funktionelle  Unterschiede  zwischen  DG  und  pPV 
Vorläuferzellpopulationen identifiziert  werden.  Im DG wurden Nestin-positive  Zellen  mit 
einer  sternförmigen  Morphologie  gefunden,  während  im  pPV  elliptisch  geformte  Nestin-
positive Zellen auftraten. Eine bFGF-Behandlung verursachte eine schnelle aber kurzlebige 
neurogene Antwort  im DG, wobei  bFGF im pPV einen ausgeprägteren und langlebigeren 
neurogenen Effekt bewirkte. 
Wenn  die  OHC einer  40  min  OGD ausgesetzt  wurden,  war  eine  Aktivierung der 
Mikroglia und die Hochregulation von IL-1ß-, TNF-α- und IL-6-mRNA (2h nach OGD) zu 
beobachteten, die der Entwicklung der neuronalen Schädigung (6h nach OGD) und einem 
Anstieg der Zellproliferation (16h nach OGD) voranging. Eine Behandlung mit BDNF, EGF 
oder NGF verminderte die OGD-induzierte Proliferation. Die Neurogenese war an Tag 3 nach 
OGD in beiden neurogenen Zonen gehemmt. Die Wiederherstellung der Neurogenese konnte 
aber bereits am Tag 6 beobachtet werden. Zu diesem Zeitpunkt wurde eine im Vergleich zur 
Kontrolle signifikante Erhöhung der Anzahl neugebildeter Neurone im pPV gefunden. Die 
Zahl BrdU/ß-III Tubulin-positiven Neurone im pPV OGD-exponierter OHC konnte durch die 
Gabe von bFGF erheblich gesteigert werden. 
MK-801, Indomethacin oder Minozyklin verhinderten die OGD-induzierte neuronale 
Schädigung, Zellproliferation und verursachten eine Abnahme von OX-42 positiver Mikroglia 
im geschädigten Bereich. Unter Kontrollbedingungen induzierten MK-801, Indomethacin und 
Minozyklin  Neurogenese  im pPV. Nach OGD verminderte  eine MK-801 Behandlung die 
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Zahl der BrdU/DCX-positiven Zellen des pPV. Indomethacin oder Minozyklin beeinflussten 
die OGD-induzierte Neurogenese im pPV jedoch nicht. 
Zusammenfassend zeigt diese Studie  erstmals i)  dass es in  als  Oberflächenschnitte 
kultivierten OHC zwei neurogene Zonen gibt, den DG und den pPV ii) das DG und pPV 
neuronale  Vorläuferzellen  mit  unterschiedlichen  neurogenen  Eigenschaften  enthalten.  Die 
Neurogenese im pPV war hoch, während die Neurogenese im DG von OHC niedrig war; iii) 
eine Entzündung tritt in OHC schon zu einem frühen Zeitpunkt nach OGD auf. Sie ist mit der 
Aktivierung, Migration und Proliferation von Mikroglia verbunden; iv) wegen Änderungen 
des Mikromilieus  wird die  Neurogenese in  beiden  neurogenen Zonen früh  nach OGD (3 
Tage) gehemmt und später (6 Tage) wieder hergestellt. OGD regt die Neurogenese im pPV 
an;  v)  Neuroprotektion  gegen  OGD-induzierte  Schädigung  durch  anti-inflammatorische 
Behandlung ist in OHC von intakter Neurogenese begleitet. Somit lieferten die in vitro Daten 
wichtige Hinweise, die für ein weiteres Verständnis der Mechanismen der Neurogenese und 
der anti-inflammatorischen Behandlung nach Schlaganfall nützlich sein könnten. 
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